Diabetes & Metabolism Journal

Review

Cardiovascular Risk/Epidemiology
Intensified Multifactorial Intervention in Patients with Type 2 Diabetes Mellitus: Takayoshi Sasako, Toshimasa Yamauchi, Kohjiro Ueki; Diabetes Metab J. 2023;47(2):185-197. Published online January 12, 2023; DOI: https://doi.org/10.4093/dmj.2022.0325

3,156 View
303 Download
2 Citations

In the management of diabetes mellitus, one of the most important goals is to prevent its micro- and macrovascular complications, and to that end, multifactorial intervention is widely recommended. Intensified multifactorial intervention with pharmacotherapy for associated risk factors, alongside lifestyle modification, was first shown to be efficacious in patients with microalbuminuria (Steno-2 study), then in those with less advanced microvascular complications (the Anglo-Danish-Dutch Study of Intensive Treatment In People with Screen Detected Diabetes in Primary Care [ADDITION]-Europe and the Japan Diabetes Optimal Treatment study for 3 major risk factors of cardiovascular diseases [J-DOIT3]), and in those with advanced microvascular complications (the Nephropathy In Diabetes-Type 2 [NID-2] study and Diabetic Nephropathy Remission and Regression Team Trial in Japan [DNETT-Japan]). Thus far, multifactorial intervention led to a reduction in cardiovascular and renal events, albeit not necessarily significant. It should be noted that not only baseline characteristics but also the control status of the risk factors and event rates during intervention among the patients widely varied from one trial to the next. Further evidence is needed for the efficacy of multifactorial intervention in a longer duration and in younger or elderly patients. Moreover, now that new classes of antidiabetic drugs are available, it should be addressed whether strict and safe glycemic control, alongside control of other risk factors, could lead to further risk reductions in micro- and macrovascular complications, thereby decreasing all-cause mortality in patients with type 2 diabetes mellitus.

Citations

Citations to this article as recorded by

Cardiovascular Risk Reduction in Type 2 Diabetes: Further Insights into the Power of Weight Loss and Exercise
Seung-Hwan Lee
Endocrinology and Metabolism.2023; 38(3): 302. CrossRef
Sarcopenia: Loss of mighty armor against frailty and aging
Takayoshi Sasako, Kohjiro Ueki
Journal of Diabetes Investigation.2023; 14(10): 1145. CrossRef

Original Articles

Type 1 Diabetes
Performance of Fast-Acting Aspart Insulin as Compared to Aspart Insulin in Insulin Pump for Managing Type 1 Diabetes Mellitus: A Meta-Analysis: Deep Dutta, Ritin Mohindra, Kunal Mahajan, Meha Sharma; Diabetes Metab J. 2023;47(1):72-81. Published online June 24, 2022; DOI: https://doi.org/10.4093/dmj.2022.0035

3,456 View
227 Download

Abstract PDF Supplementary Material PubReader ePub: Background
No meta-analysis has analysed efficacy and safety of fast-acting aspart insulin (FIAsp) with insulin pump in type 1 diabetes mellitus (T1DM).
Methods
Electronic databases were searched for randomised controlled trials (RCTs) involving T1DM patients on insulin pump receiving FIAsp in intervention arm, and placebo/active comparator insulin in control arm. Primary outcome was to evaluate changes in 1- and 2-hour post-prandial glucose (1hPPG and 2hPPG). Secondary outcomes were to evaluate alterations in percentage time with blood glucose <3.9 mmol/L (hypoglycaemia), time in range (TIR) blood glucose 3.9 to 10 mmol/L, insulin requirements and adverse events.
Results
Data from four RCTs involving 640 patients was analysed. FIAsp use in insulin pump was associated with significantly greater lowering of 1hPPG (mean difference [MD], –1.35 mmol/L; 95% confidence interval [CI], –1.72 to –0.98; P<0.01; I²=63%) and 2hPPG (MD, –1.19 mmol/L; 95% CI, –1.38 to –1.00; P<0.01; I²=0%) as compared to controls. TIR was comparable among groups (MD, 1.06%; 95% CI, –3.84 to 5.96; P=0.67; I²=70%). Duration of blood glucose <3.9 mmol/L was lower in FIAsp group, approaching significance (MD, –0.91%; 95% CI, –1.84 to 0.03; P=0.06; I²=0%). Total hypoglycaemic episodes (risk ratio [RR], 1.35; 95% CI, 0.55 to 3.31; P=0.51; I²=0%), severe hypoglycaemia (RR, 2.26; 95% CI, 0.77 to 6.66; P=0.14), infusion site reactions (RR, 1.35; 95% CI, 0.63 to 2.93; P=0.77; I²=0%), and treatment-emergent adverse events (RR, 1.13; 95% CI, 0.80 to 1.60; P=0.50; I²=0%) were comparable.
Conclusion
FIAsp use in insulin pump is associated with better post-prandial glycaemic control with no increased hypoglycaemia or glycaemic variability.

Metabolic Risk/Epidemiology
Reproductive Life Span and Severe Hypoglycemia Risk in Postmenopausal Women with Type 2 Diabetes Mellitus: Soyeon Kang, Yong-Moon Park, Dong Jin Kwon, Youn-Jee Chung, Jeong Namkung, Kyungdo Han, Seung-Hyun Ko; Diabetes Metab J. 2022;46(4):578-591. Published online January 24, 2022; DOI: https://doi.org/10.4093/dmj.2021.0135

4,387 View
220 Download
3 Citations

Abstract PDF Supplementary Material PubReader ePub

Background
Estrogen promotes glucose homeostasis, enhances insulin sensitivity, and maintains counterregulatory responses in recurrent hypoglycemia in women of reproductive age. Postmenopausal women with type 2 diabetes mellitus (T2DM) might be more vulnerable to severe hypoglycemia (SH) events. However, the relationship between reproductive factors and SH occurrence in T2DM remains unelucidated.
Methods
This study included data on 181,263 women with postmenopausal T2DM who participated in a national health screening program from January 1 to December 31, 2009, obtained using the Korean National Health Insurance System database. Outcome data were obtained until December 31, 2018. Associations between reproductive factors and SH incidence were assessed using Cox proportional hazards models.
Results
During the mean follow-up of 7.9 years, 11,279 (6.22%) postmenopausal women with T2DM experienced SH episodes. A longer reproductive life span (RLS) (≥40 years) was associated with a lower SH risk compared to a shorter RLS (<30 years) (adjusted hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.69 to 0.80; P for trend <0.001) after multivariable adjustment. SH risk decreased with every 5-year increment of RLS (with <30 years as a reference [adjusted HR, 0.91; 95% CI, 0.86 to 0.95; P=0.0001 for 30−34 years], [adjusted HR, 0.80; 95% CI, 0.76 to 0.84; P<0.001 for 35−39 years], [adjusted HR, 0.74; 95% CI, 0.68 to 0.81; P<0.001 for ≥40 years]). The use of hormone replacement therapy (HRT) was associated with a lower SH risk than HRT nonuse.
Conclusion
Extended exposure to endogenous ovarian hormone during lifetime may decrease the number of SH events in women with T2DM after menopause.

Citations

Citations to this article as recorded by

Association between serum copper level and reproductive health of Women in the United States: a cross-sectional study
Yi Yuan, Tong-Yu Peng, Guang-Yuan Yu, Zhao Zou, Meng-Ze Wu, Ruofei Zhu, Shuang Wu, Zi Lv, Su-Xin Luo
International Journal of Environmental Health Research.2023; : 1. CrossRef
Reproductive Lifespan and Motor Progression of Parkinson’s Disease
Ruwei Ou, Qianqian Wei, Yanbing Hou, Lingyu Zhang, Kuncheng Liu, Junyu Lin, Tianmi Yang, Jing Yang, Zheng Jiang, Wei Song, Bei Cao, Huifang Shang
Journal of Clinical Medicine.2022; 11(20): 6163. CrossRef
Menopause and development of Alzheimer’s disease: Roles of neural glucose metabolism and Wnt signaling
Paulina Villaseca, Pedro Cisternas, Nibaldo C. Inestrosa
Frontiers in Endocrinology.2022;[Epub] CrossRef

Review

Technology/Device
Current Advances of Artificial Pancreas Systems: A Comprehensive Review of the Clinical Evidence: Sun Joon Moon, Inha Jung, Cheol-Young Park; Diabetes Metab J. 2021;45(6):813-839. Published online November 22, 2021; DOI: https://doi.org/10.4093/dmj.2021.0177

11,854 View
706 Download
24 Citations

Graphical Abstract Abstract PDF Supplementary Material PubReader ePub

Since Banting and Best isolated insulin in the 1920s, dramatic progress has been made in the treatment of type 1 diabetes mellitus (T1DM). However, dose titration and timely injection to maintain optimal glycemic control are often challenging for T1DM patients and their families because they require frequent blood glucose checks. In recent years, technological advances in insulin pumps and continuous glucose monitoring systems have created paradigm shifts in T1DM care that are being extended to develop artificial pancreas systems (APSs). Numerous studies that demonstrate the superiority of glycemic control offered by APSs over those offered by conventional treatment are still being published, and rapid commercialization and use in actual practice have already begun. Given this rapid development, keeping up with the latest knowledge in an organized way is confusing for both patients and medical staff. Herein, we explore the history, clinical evidence, and current state of APSs, focusing on various development groups and the commercialization status. We also discuss APS development in groups outside the usual T1DM patients and the administration of adjunct agents, such as amylin analogues, in APSs.

Citations

Citations to this article as recorded by

100 Years of insulin: A chemical engineering perspective
B. Wayne Bequette
Korean Journal of Chemical Engineering.2023; 40(1): 1. CrossRef
Efficacy of intermittent short‐term use of a real‐time continuous glucose monitoring system in non‐insulin–treated patients with type 2 diabetes: A randomized controlled trial
Sun Joon Moon, Kyung‐Soo Kim, Woo Je Lee, Mi Yeon Lee, Robert Vigersky, Cheol‐Young Park
Diabetes, Obesity and Metabolism.2023; 25(1): 110. CrossRef
Identifiable prediction animal model for the bi-hormonal intraperitoneal artificial pancreas
Karim Davari Benam, Hasti Khoshamadi, Marte Kierulf Åm, Øyvind Stavdahl, Sebastien Gros, Anders Lyngvi Fougner
Journal of Process Control.2023; 121: 13. CrossRef
Advances in Continuous Glucose Monitoring and Integrated Devices for Management of Diabetes with Insulin-Based Therapy: Improvement in Glycemic Control
Jee Hee Yoo, Jae Hyeon Kim
Diabetes & Metabolism Journal.2023; 47(1): 27. CrossRef
CGM accuracy: Contrasting CE marking with the governmental controls of the USA (FDA) and Australia (TGA): A narrative review
John S Pemberton, Emma G Wilmot, Katharine Barnard‐Kelly, Lalantha Leelarathna, Nick Oliver, Tabitha Randell, Craig E Taplin, Pratik Choudhary, Peter Adolfsson
Diabetes, Obesity and Metabolism.2023; 25(4): 916. CrossRef
Evaluation of awareness and attitude of paediatric nursing students, nurses, and adolescents regarding type one diabetes advanced devices and virtual nursing
Howaida Moawad Ahmed Ali
Kontakt.2023; 25(2): 100. CrossRef
Predicting the output error of the suboptimal state estimator to improve the performance of the MPC-based artificial pancreas
Martin Dodek, Eva Miklovičová
Control Theory and Technology.2023; 21(4): 541. CrossRef
A Markov Model of Gap Occurrence in Continuous Glucose Monitoring Data for Realistic in Silico Clinical Trials
Martina Vettoretti, Martina Drecogna, Simone Del Favero, Andrea Facchinetti, Giovanni Sparacino
Computer Methods and Programs in Biomedicine.2023; 240: 107700. CrossRef
Drug delivery breakthrough technologies – A perspective on clinical and societal impact
Beate Bittner, Manuel Sánchez-Félix, Dennis Lee, Athanas Koynov, Joshua Horvath, Felix Schumacher, Simon Matoori
Journal of Controlled Release.2023; 360: 335. CrossRef
Importance of continuous glucose monitoring in the treatment of diabetes mellitus
Sun Joon Moon, Won-Young Lee
Journal of the Korean Medical Association.2023; 66(7): 432. CrossRef
Constrained Versus Unconstrained Model Predictive Control for Artificial Pancreas
Chiara Toffanin, Lalo Magni
IEEE Transactions on Control Systems Technology.2023; 31(5): 2288. CrossRef
Intelligent Insulin vs. Artificial Intelligence for Type 1 Diabetes: Will the Real Winner Please Stand Up?
Valentina Maria Cambuli, Marco Giorgio Baroni
International Journal of Molecular Sciences.2023; 24(17): 13139. CrossRef
Artificial Intelligence in Efficient Diabetes Care
Gopal Bhagwan Khodve, Sugato Banerjee
Current Diabetes Reviews.2023;[Epub] CrossRef
The artificial pancreas: two alternative approaches to achieve a fully closed-loop system with optimal glucose control
M. K. Åm, I. A. Teigen, M. Riaz, A. L. Fougner, S. C. Christiansen, S. M. Carlsen
Journal of Endocrinological Investigation.2023;[Epub] CrossRef
Multivariable Automated Insulin Delivery System for Handling Planned and Spontaneous Physical Activities
Mohammad Reza Askari, Mohammad Ahmadasas, Andrew Shahidehpour, Mudassir Rashid, Laurie Quinn, Minsun Park, Ali Cinar
Journal of Diabetes Science and Technology.2023; 17(6): 1456. CrossRef
Advanced Technology (Continuous Glucose Monitoring and Advanced Hybrid Closed-Loop Systems) in Diabetes from the Perspective of Gender Differences
Maria Grazia Nuzzo, Marciano Schettino
Diabetology.2023; 4(4): 519. CrossRef
Integration of a Safety Module to Prevent Rebound Hypoglycemia in Closed-Loop Artificial Pancreas Systems
María F. Villa-Tamayo, Patricio Colmegna, Marc D. Breton
Journal of Diabetes Science and Technology.2023;[Epub] CrossRef
The effects of acute hyperglycaemia on sports and exercise performance in type 1 diabetes: a systematic review and meta-analysis
Bonar McGuire, Hashim Dadah, Dominic Oliver
Journal of Science and Medicine in Sport.2023;[Epub] CrossRef
Artificial Pancreas under a Zone Model Predictive Control based on Gaussian Process models: toward the personalization of the closed loop
Marco Polver, Beatrice Sonzogni, Mirko Mazzoleni, Fabio Previdi, Antonio Ferramosca
IFAC-PapersOnLine.2023; 56(2): 9642. CrossRef
Personalized Constrained MPC for glucose regulation
Chiara Toffanin, Lalo Magni
IFAC-PapersOnLine.2023; 56(2): 9648. CrossRef
Novel Glycemic Index Based on Continuous Glucose Monitoring to Predict Poor Clinical Outcomes in Critically Ill Patients: A Pilot Study
Eun Yeong Ha, Seung Min Chung, Il Rae Park, Yin Young Lee, Eun Young Choi, Jun Sung Moon
Frontiers in Endocrinology.2022;[Epub] CrossRef
Dual‐hormone artificial pancreas for glucose control in type 1 diabetes: A meta‐analysis
Baoqi Zeng, Hao Jia, Le Gao, Qingqing Yang, Kai Yu, Feng Sun
Diabetes, Obesity and Metabolism.2022; 24(10): 1967. CrossRef
Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Systematic Review
Alezandra Torres-Castaño, Amado Rivero-Santana, Lilisbeth Perestelo-Pérez, Andrea Duarte-Díaz, Analia Abt-Sacks, Vanesa Ramos-García, Yolanda Álvarez-Pérez, Ana M. Wäagner, Mercedes Rigla, Pedro Serrano-Aguilar
Applied Sciences.2022; 12(20): 10262. CrossRef
History of insulin treatment of pediatric patients with diabetes in Korea
Jae Hyun Kim, Choong Ho Shin, Sei Won Yang
Annals of Pediatric Endocrinology & Metabolism.2021; 26(4): 237. CrossRef

Original Article

Drug/Regimen
Efficacy and Safety of Self-Titration Algorithms of Insulin Glargine 300 units/mL in Individuals with Uncontrolled Type 2 Diabetes Mellitus (The Korean TITRATION Study): A Randomized Controlled Trial: Jae Hyun Bae, Chang Ho Ahn, Ye Seul Yang, Sun Joon Moon, Soo Heon Kwak, Hye Seung Jung, Kyong Soo Park, Young Min Cho; Diabetes Metab J. 2022;46(1):71-80. Published online June 16, 2021; DOI: https://doi.org/10.4093/dmj.2020.0274

6,444 View
400 Download
3 Citations

Graphical Abstract Abstract PDF Supplementary Material PubReader ePub

Background
To compare the efficacy and safety of two insulin self-titration algorithms, Implementing New Strategies with Insulin Glargine for Hyperglycemia Treatment (INSIGHT) and EDITION, for insulin glargine 300 units/mL (Gla-300) in Korean individuals with uncontrolled type 2 diabetes mellitus (T2DM).
Methods
In a 12-week, randomized, open-label trial, individuals with uncontrolled T2DM requiring basal insulin were randomized to either the INSIGHT (adjusted by 1 unit/day) or EDITION (adjusted by 3 units/week) algorithm to achieve a fasting self-monitoring of blood glucose (SMBG) in the range of 4.4 to 5.6 mmol/L. The primary outcome was the proportion of individuals achieving a fasting SMBG ≤5.6 mmol/L without noct urnal hypoglycemia at week 12.
Results
Of 129 individuals (age, 64.1±9.5 years; 66 [51.2%] women), 65 and 64 were randomized to the INSIGHT and EDITION algorithms, respectively. The primary outcome of achievement was comparable between the two groups (24.6% vs. 23.4%, P=0.876). Compared with the EDITION group, the INSIGHT group had a greater reduction in 7-point SMBG but a similar decrease in fasting plasma glucose and glycosylated hemoglobin. The increment of total daily insulin dose was significantly higher in the INSIGHT group than in the EDITION group (between-group difference: 5.8±2.7 units/day, P=0.033). However, body weight was significantly increased only in the EDITION group (0.6±2.4 kg, P=0.038). There was no difference in the occurrence of hypoglycemia between the two groups. Patient satisfaction was significantly increased in the INSIGHT group (P=0.014).
Conclusion
The self-titration of Gla-300 using the INSIGHT algorithm was effective and safe compared with that using the EDITION algorithm in Korean individuals with uncontrolled T2DM (ClinicalTrials.gov number: NCT03406663).

Citations

Citations to this article as recorded by

Basal insulin titration algorithms in patients with type 2 diabetes: the simplest is the best (?)
V.I. Katerenchuk
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2023; 19(1): 72. CrossRef
Issues of insulin therapy for type 2 diabetes and ways to solve them
V.I. Katerenchuk, A.V. Katerenchuk
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2023; 19(3): 240. CrossRef
Time for Using Machine Learning for Dose Guidance in Titration of People With Type 2 Diabetes? A Systematic Review of Basal Insulin Dose Guidance
Camilla Heisel Nyholm Thomsen, Stine Hangaard, Thomas Kronborg, Peter Vestergaard, Ole Hejlesen, Morten Hasselstrøm Jensen
Journal of Diabetes Science and Technology.2022; : 193229682211459. CrossRef

Review

Type 1 Diabetes
Non-Insulin Antidiabetes Treatment in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis: Xiaoling Cai, Chu Lin, Wenjia Yang, Lin Nie, Linong Ji; Diabetes Metab J. 2021;45(3):312-325. Published online March 15, 2021; DOI: https://doi.org/10.4093/dmj.2020.0171

5,433 View
256 Download
3 Citations

Graphical Abstract Abstract PDF Supplementary Material PubReader ePub

In order to evaluate the efficacy and side effects of the non-insulin antidiabetes medications as an adjunct treatment in type 1 diabetes mellitus (T1DM), we conducted systematic searches in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials for randomized controlled trials published between the date of inception and March 2020 to produce a systematic review and meta-analysis. Overall, 57 studies were included. Compared with placebo, antidiabetes agents in adjunct to insulin treatment resulted in significant reduction in glycosylated hemoglobin (weighted mean difference [WMD], –0.30%; 95% confidence interval [CI], –0.34 to –0.25%; P<0.01) and body weight (WMD, –2.15 kg; 95% CI, –2.77 to –1.53 kg; P<0.01), and required a significantly lower dosage of insulin (WMD, –5.17 unit/day; 95% CI, –6.77 to –3.57 unit/day; P<0.01). Compared with placebo, antidiabetes agents in adjunct to insulin treatment increased the risk of hypoglycemia (relative risk [RR], 1.04; 95% CI, 1.01 to 1.08; P=0.02) and gastrointestinal side effects (RR, 1.99; 95% CI, 1.61 to 2.46; P<0.01) in patients with T1DM. Compared with placebo, the use of non-insulin antidiabetes agents in addition to insulin could lead to glycemic improvement, weight control and lower insulin dosage, while they might be associated with increased risks of hypoglycemia and gastrointestinal side effects in patients with T1DM.

Citations

Citations to this article as recorded by

The Impact of Body Mass Index, Residual Beta Cell Function and Estimated Glucose Disposal Rate on the Development of Double Diabetes and Microvascular Complications in Patients With Type 1 Diabetes Mellitus
Rameez Raja Bhagadurshah, Subbiah Eagappan, Raghavan Kasthuri Santharam, Sridhar Subbiah
Cureus.2023;[Epub] CrossRef
Type 1 diabetes glycemic management: Insulin therapy, glucose monitoring, and automation
Bruce A. Perkins, Jennifer L. Sherr, Chantal Mathieu
Science.2021; 373(6554): 522. CrossRef
Current Advances of Artificial Pancreas Systems: A Comprehensive Review of the Clinical Evidence
Sun Joon Moon, Inha Jung, Cheol-Young Park
Diabetes & Metabolism Journal.2021; 45(6): 813. CrossRef

Original Articles

Complications
Differences in Clinical Outcomes between Patients with and without Hypoglycemia during Hospitalization: A Retrospective Study Using Real-World Evidence: Jeongmin Lee, Tong Min Kim, Hyunah Kim, Seung-Hwan Lee, Jae Hyoung Cho, Hyunyong Lee, Hyeon Woo Yim, Kun-Ho Yoon, Hun-Sung Kim; Diabetes Metab J. 2020;44(4):555-565. Published online May 8, 2020; DOI: https://doi.org/10.4093/dmj.2019.0064

5,689 View
96 Download
8 Citations

Abstract PDF Supplementary Material PubReader ePub

Background

Some patients admitted to hospitals for glycemic control experience hypoglycemia despite regular meals and despite adhering to standard blood glucose control protocols. Different factors can have a negative impact on blood glucose control and prognosis after discharge. This study investigated risk factors for hypoglycemia and its effects on glycemic control during the hospitalization of patients in the general ward.

Methods

This retrospective study included patients who were admitted between 2009 and 2018. Patients were provided regular meals at fixed times according to ideal body weights during hospitalization. We categorized the patients into two groups: those with and those without hypoglycemia during hospitalization.

Results

Of the 3,031 patients, 379 experienced at least one episode of hypoglycemia during hospitalization (HYPO group). Hypoglycemia occurred more frequently particularly in cases of premixed insulin therapy. Compared with the control group, the HYPO group was older (61.0±16.8 years vs. 59.1±16.5 years, P=0.035), with more females (60.4% vs. 49.6%, P<0.001), lower body mass index (BMI) (23.5±4.2 kg/m² vs. 25.1±4.4 kg/m², P<0.001), and higher prevalence of type 1 diabetes mellitus (6.1% vs. 2.6%, P<0.001), They had longer hospital stay (11.1±13.5 days vs. 7.6±4.6 days, P<0.001). After discharge the HYPO group had lower glycosylated hemoglobin reduction rate (−2.0%±0.2% vs. −2.5%±0.1%, P=0.003) and tended to have more frequent cases of cardiovascular disease.

Conclusion

Hypoglycemia occurred more frequently in older female patients with lower BMI and was associated with longer hospital stay and poorer glycemic control after discharge. Therefore, clinicians must carefully ensure that patients do not experience hypoglycemia during hospitalization.

Citations

Citations to this article as recorded by

Acute kidney injury: a strong risk factor for hypoglycaemia in hospitalized patients with type 2 diabetes
Ana Carreira, Pedro Castro, Filipe Mira, Miguel Melo, Pedro Ribeiro, Lèlita Santos
Acta Diabetologica.2023; 60(9): 1179. CrossRef
Adherence to healthy lifestyle behaviors as a preventable risk factor for severe hypoglycemia in people with type 2 diabetes: A longitudinal nationwide cohort study
Jae‐Seung Yun, Kyungdo Han, Yong‐Moon Park, Eugene Han, Yong‐ho Lee, Seung‐Hyun Ko
Journal of Diabetes Investigation.2022; 13(9): 1533. CrossRef
Predicting hypoglycemia in hospitalized patients with diabetes: A derivation and validation study
Michal Elbaz, Jeries Nashashibi, Shiri Kushnir, Leonard Leibovici
Diabetes Research and Clinical Practice.2021; 171: 108611. CrossRef
Hospital care: improving outcomes in type 1 diabetes
Schafer Boeder, Kristen Kulasa
Current Opinion in Endocrinology, Diabetes & Obesity.2021; 28(1): 14. CrossRef
Data Pseudonymization in a Range That Does Not Affect Data Quality: Correlation with the Degree of Participation of Clinicians
Soo-Yong Shin, Hun-Sung Kim
Journal of Korean Medical Science.2021;[Epub] CrossRef
Letter: Differences in Clinical Outcomes between Patients with and without Hypoglycemia during Hospitalization: A Retrospective Study Using Real-World Evidence (Diabetes Metab J 2020;44:555-65)
Sung-Woo Kim
Diabetes & Metabolism Journal.2020; 44(5): 775. CrossRef
Response: Differences in Clinical Outcomes between Patients with and without Hypoglycemia during Hospitalization: A Retrospective Study Using Real-World Evidence (Diabetes Metab J 2020;44:555-65)
Jeongmin Lee, Hun-Sung Kim
Diabetes & Metabolism Journal.2020; 44(5): 779. CrossRef
Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes
Niki Katsiki, Kalliopi Kotsa, Anca P. Stoian, Dimitri P. Mikhailidis
Current Pharmaceutical Design.2020; 26(43): 5637. CrossRef

Drug/Regimen
Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial: Kyu Yong Cho, Akinobu Nakamura, Chiho Oba-Yamamoto, Kazuhisa Tsuchida, Shingo Yanagiya, Naoki Manda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi; Diabetes Metab J. 2020;44(4):532-541. Published online November 22, 2019; DOI: https://doi.org/10.4093/dmj.2019.0093

4,797 View
144 Download
7 Citations

Abstract PDF Supplementary Material PubReader ePub

Background

To explore the efficacy and safety of switching from once-daily basal insulin therapy to once-daily pre-meal injection insulin degludec/insulin aspart (IDegAsp) with respect to the glycemic control of participants with type 2 diabetes mellitus (T2DM).

Methods

In this multicenter, open-label, prospective, randomized, parallel-group comparison trial, participants on basal insulin therapy were switched to IDegAsp (IDegAsp group; n=30) or continued basal insulin (Basal group; n=29). The primary endpoint was the superiority of IDegAsp in causing changes in the daily blood glucose profile, especially post-prandial blood glucose concentration after 12 weeks.

Results

Blood glucose concentrations after dinner and before bedtime were lower in the IDegAsp group, and the improvement in blood glucose before bedtime was significantly greater in the IDegAsp group than in the Basal group at 12 weeks (−1.7±3.0 mmol/L vs. 0.3±2.1 mmol/L, P<0.05). Intriguingly, glycemic control after breakfast was not improved by IDegAsp injection before breakfast, in contrast to the favorable effect of injection before dinner on blood glucose after dinner. Glycosylated hemoglobin significantly decreased only in the IDegAsp group (58 to 55 mmol/mol, P<0.05). Changes in daily insulin dose, body mass, and recorded adverse effects, including hypoglycemia, were comparable between groups.

Conclusion

IDegAsp was more effective than basal insulin at reducing blood glucose after dinner and before bedtime, but did not increase the incidence of hypoglycemia. Switching from basal insulin to IDegAsp does not increase the burden on the patient and positively impacts glycemic control in patients with T2DM.

Citations

Citations to this article as recorded by

Low fasting glucose‐to‐estimated average glucose ratio was associated with superior response to insulin degludec/aspart compared with basal insulin in patients with type 2 diabetes
Han Na Jang, Ye Seul Yang, Tae Jung Oh, Bo Kyung Koo, Seong Ok Lee, Kyong Soo Park, Hak Chul Jang, Hye Seung Jung
Journal of Diabetes Investigation.2022; 13(1): 85. CrossRef
Comparing time to intensification between insulin degludec/insulin aspart and insulin glargine: A single-center experience from India
Rajiv Kovil
Journal of Diabetology.2022; 13(2): 171. CrossRef
Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns
Tevfik Demir, Serap Turan, Kursad Unluhizarci, Oya Topaloglu, Tufan Tukek, Dilek Gogas Yavuz
Frontiers in Endocrinology.2021;[Epub] CrossRef
Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base
I. N. Dyakov, S. K. Zyryanov
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice.2021; 20(1): 4. CrossRef
Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis
Shinje Moon, Hye-Soo Chung, Yoon-Jung Kim, Jae-Myung Yu, Woo-Ju Jeong, Jiwon Park, Chang-Myung Oh
Metabolites.2021; 11(9): 639. CrossRef
Insulin therapy in diabetic kidney disease
Yan Liu, Chanyue Zhao, Xiaofen Xiong, Ming Yang, Lin Sun
Diabetic Nephropathy.2021; 1(2): 67. CrossRef
Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin
Anwar Ali Jammah
Primary Care Diabetes.2020;[Epub] CrossRef

Clinical Complications
Hypoglycemia and Dementia Risk in Older Patients with Type 2 Diabetes Mellitus: A Propensity-Score Matched Analysis of a Population-Based Cohort Study: Young-Gun Kim, Dong Gyu Park, So Young Moon, Ja Young Jeon, Hae Jin Kim, Dae Jung Kim, Kwan-Woo Lee, Seung Jin Han; Diabetes Metab J. 2020;44(1):125-133. Published online October 23, 2019; DOI: https://doi.org/10.4093/dmj.2018.0260

5,597 View
198 Download
26 Citations

Abstract PDF PubReader

Background

Type 2 diabetes mellitus (T2DM) is associated with an increased risk for dementia. The effects of hypoglycemia on dementia are controversial. Thus, we evaluated whether hypoglycemia increases the risk for dementia in senior patients with T2DM.

Methods

We used the Korean National Health Insurance Service Senior cohort, which includes >10% of the entire senior population of South Korea. In total, 5,966 patients who had ever experienced at least one episode of hypoglycemia were matched with those who had not, using propensity score matching. The risk of dementia was assessed through a survival analysis of matched pairs.

Results

Patients with underlying hypoglycemic events had an increased risk for all-cause dementia, Alzheimer's dementia (AD), and vascular dementia (VaD) compared with those who had not experienced a hypoglycemic event (hazard ratio [HR], 1.254; 95% confidence interval [CI], 1.166 to 1.349; P<0.001 for all-cause dementia; HR, 1.264; 95% CI, 1.162 to 1.375; P<0.001 for AD; HR, 1.286; 95% CI, 1.110 to 1.490; P<0.001 for VaD). According to number of hypoglycemic episodes, the HRs of dementia were 1.170, 1.201, and 1.358 in patients with one hypoglycemic episode, two or three episodes, and more than three episodes, respectively. In the subgroup analysis, hypoglycemia was associated with an increased risk for dementia in both sexes with or without T2DM microvascular or macrovascular complications.

Conclusion

Our findings suggest that patients with a history of hypoglycemia have a higher risk for dementia. This trend was similar for AD and VaD, the two most important subtypes of dementia.

Citations

Citations to this article as recorded by

Hypoglycaemia and the risk of dementia: a population-based cohort study using exposure density sampling
Wajd Alkabbani, Colleen J Maxwell, Ruth Ann Marrie, Suzanne L Tyas, Iliana C Lega, John-Michael Gamble
International Journal of Epidemiology.2023; 52(3): 908. CrossRef
Type 2 diabetes mellitus and cognitive function: understanding the connections
Lisa Dao, Sarah Choi, Matthew Freeby
Current Opinion in Endocrinology, Diabetes & Obesity.2023; 30(1): 7. CrossRef
Associations of Mid- and Late-Life Severe Hypoglycemic Episodes With Incident Dementia Among Patients With Type 2 Diabetes: A Population-Based Cohort Study
Wajd Alkabbani, Colleen J. Maxwell, Ruth Ann Marrie, Suzanne L. Tyas, Iliana C. Lega, John-Michael Gamble
Diabetes Care.2023; 46(2): 331. CrossRef
Nocturnal hypoglycemia is underdiagnosed in older people with insulin‐treated type 2 diabetes: The HYPOAGE observational study
Anne‐Sophie Boureau, Béatrice Guyomarch, Pierre Gourdy, Ingrid Allix, Cédric Annweiler, Nathalie Cervantes, Guillaume Chapelet, Isabelle Delabrière, Sophie Guyonnet, Rachel Litke, Marc Paccalin, Alfred Penfornis, Pierre‐Jean Saulnier, Matthieu Wargny, Sam
Journal of the American Geriatrics Society.2023; 71(7): 2107. CrossRef
Dementia in Diabetes: The Role of Hypoglycemia
Khaled Hameed Husain, Saud Faisal Sarhan, Haya Khaled Ali Abdulla AlKhalifa, Asal Buhasan, Abu Saleh Md Moin, Alexandra E. Butler
International Journal of Molecular Sciences.2023; 24(12): 9846. CrossRef
Association Between Trajectory of Severe Hypoglycemia and Dementia in Patients With Type 2 Diabetes: A Population-based Study
Chung-Yi Li, Chia-Lun Kuo, Ya-Hui Chang, Chin-Li Lu, Santi Martini, Wen-Hsuan Hou
Journal of Epidemiology.2022; 32(9): 423. CrossRef
Severe Hypoglycemia Increases Dementia Risk and Related Mortality: A Nationwide, Population-based Cohort Study
Eugene Han, Kyung-do Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Seung-Hyun Ko, Yong-ho Lee
The Journal of Clinical Endocrinology & Metabolism.2022; 107(5): e1976. CrossRef
Association between hypoglycemia and dementia in patients with diabetes: a systematic review and meta-analysis of 1.4 million patients
Lifen Huang, Manlian Zhu, Jie Ji
Diabetology & Metabolic Syndrome.2022;[Epub] CrossRef
Potential Roles of Glucagon-Like Peptide-1 and Its Analogues in Dementia Targeting Impaired Insulin Secretion and Neurodegeneration
Sidharth Mehan, Sonalika Bhalla, Ehraz Mehmood Siddiqui, Nidhi Sharma, Ambika Shandilya, Andleeb Khan
Degenerative Neurological and Neuromuscular Disease.2022; Volume 12: 31. CrossRef
Immortal time bias for life-long conditions in retrospective observational studies using electronic health records
Freya Tyrer, Krishnan Bhaskaran, Mark J. Rutherford
BMC Medical Research Methodology.2022;[Epub] CrossRef
Glucose-lowering drugs, cognition, and dementia: The clinical evidence
Che-Yuan Wu, Lila Shapiro, Michael Ouk, Bradley J. MacIntosh, Sandra E. Black, Baiju R. Shah, Walter Swardfager
Neuroscience & Biobehavioral Reviews.2022; 137: 104654. CrossRef
Switching insulin degludec to insulin glulisine improved nocturnal hypoglycemia and ventricular arrythmia in an elderly type 1 diabetes patient with chronic heart failure: A case report
Yuriko Hajika, Yuji Kawaguchi, Takako Tanaka, Kenji Hamazaki, Yasuro Kumeda
Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics.2022; 59(2): 237. CrossRef
Diagnostic, Prognostic, and Mechanistic Biomarkers of Diabetes Mellitus-Associated Cognitive Decline
Hanan Ehtewish, Abdelilah Arredouani, Omar El-Agnaf
International Journal of Molecular Sciences.2022; 23(11): 6144. CrossRef
Amyloid $$upbeta$$ (1–42) peptide impairs mitochondrial respiration in primary human brain microvascular endothelial cells: impact of dysglycemia and pre-senescence
Siva S. V. P. Sakamuri, Venkata N. Sure, Xiaoying Wang, Gregory Bix, Vivian A. Fonseca, Ricardo Mostany, Prasad V. G. Katakam
GeroScience.2022; 44(6): 2721. CrossRef
Mechanistic Role of Jak3 in Obesity-Associated Cognitive Impairments
Premranjan Kumar, Jayshree Mishra, Narendra Kumar
Nutrients.2022; 14(18): 3715. CrossRef
Assessing real-world effectiveness of therapies: what is the impact of incretin-based treatments on hospital use for patients with type 2 diabetes?
Clémence Bussiere, Pauline Chauvin, Jean-Michel Josselin, Christine Sevilla-Dedieu
Health Economics Review.2022;[Epub] CrossRef
Fasting Glucose Variability and the Risk of Dementia in Individuals with Diabetes: A Nationwide Cohort Study
Da Young Lee, Jaeyoung Kim, Sanghyun Park, So Young Park, Ji Hee Yu, Ji A Seo, Nam Hoon Kim, Hye Jin Yoo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Kyungdo Han, Nan Hee Kim
Diabetes & Metabolism Journal.2022; 46(6): 923. CrossRef
Meta-Analysis: Association Between Hypoglycemia and Serious Adverse Events in Older Patients Treated With Glucose-Lowering Agents
Katharina Mattishent, Yoon K. Loke
Frontiers in Endocrinology.2021;[Epub] CrossRef
Hypoglycemia, Vascular Disease and Cognitive Dysfunction in Diabetes: Insights from Text Mining-Based Reconstruction and Bioinformatics Analysis of the Gene Networks
Olga V. Saik, Vadim V. Klimontov
International Journal of Molecular Sciences.2021; 22(22): 12419. CrossRef
Muscle strength, an independent determinant of glycemic control in older adults with long-standing type 2 diabetes: a prospective cohort study
Bo Kyung Koo, Seoil Moon, Min Kyong Moon
BMC Geriatrics.2021;[Epub] CrossRef
Optimal Type 2 Diabetes Mellitus Management and Active Ageing
Alessia Maria Calabrese, Valeria Calsolaro, Sara Rogani, Chukwuma Okoye, Nadia Caraccio, Fabio Monzani
Endocrines.2021; 2(4): 523. CrossRef
Response: Hypoglycemia and Dementia Risk in Older Patients with Type 2 Diabetes Mellitus: A Propensity-Score Matched Analysis of a Population-Based Cohort Study (Diabetes Metab J 2020;44:125–33)
Seung Jin Han
Diabetes & Metabolism Journal.2020; 44(2): 360. CrossRef
Severe hypoglycaemia and absolute risk of cause-specific mortality in individuals with type 2 diabetes: a UK primary care observational study
Francesco Zaccardi, Suping Ling, Claire Lawson, Melanie J. Davies, Kamlesh Khunti
Diabetologia.2020; 63(10): 2129. CrossRef
Letter: Hypoglycemia and Dementia Risk in Older Patients with Type 2 Diabetes Mellitus: A Propensity-Score Matched Analysis of a Population-Based Cohort Study (Diabetes Metab J 2020;44:125–33)
Jin Hwa Kim
Diabetes & Metabolism Journal.2020; 44(2): 356. CrossRef
Low‐glucose‐sensitive TRPC6 dysfunction drives hypoglycemia‐induced cognitive impairment in diabetes
Chengkang He, Peng Gao, Yuanting Cui, Qiang Li, Yingsha Li, Zongshi Lu, Huan Ma, Yu Zhao, Li Li, Fang Sun, Xiaowei Chen, Hongbo Jia, Daoyan Liu, Gangyi Yang, Hongting Zheng, Zhiming Zhu
Clinical and Translational Medicine.2020;[Epub] CrossRef
Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes
Niki Katsiki, Kalliopi Kotsa, Anca P. Stoian, Dimitri P. Mikhailidis
Current Pharmaceutical Design.2020; 26(43): 5637. CrossRef

Review

Others
Continuous Glucose Monitoring Sensors for Diabetes Management: A Review of Technologies and Applications: Giacomo Cappon, Martina Vettoretti, Giovanni Sparacino, Andrea Facchinetti; Diabetes Metab J. 2019;43(4):383-397. Published online July 25, 2019; DOI: https://doi.org/10.4093/dmj.2019.0121

17,663 View
810 Download
170 Citations

Abstract PDF PubReader

By providing blood glucose (BG) concentration measurements in an almost continuous-time fashion for several consecutive days, wearable minimally-invasive continuous glucose monitoring (CGM) sensors are revolutionizing diabetes management, and are becoming an increasingly adopted technology especially for diabetic individuals requiring insulin administrations. Indeed, by providing glucose real-time insights of BG dynamics and trend, and being equipped with visual and acoustic alarms for hypo- and hyperglycemia, CGM devices have been proved to improve safety and effectiveness of diabetes therapy, reduce hypoglycemia incidence and duration, and decrease glycemic variability. Furthermore, the real-time availability of BG values has been stimulating the realization of new tools to provide patients with decision support to improve insulin dosage tuning and infusion. The aim of this paper is to offer an overview of current literature and future possible developments regarding CGM technologies and applications. In particular, first, we outline the technological evolution of CGM devices through the last 20 years. Then, we discuss about the current use of CGM sensors from patients affected by diabetes, and, we report some works proving the beneficial impact provided by the adoption of CGM. Finally, we review some recent advanced applications for diabetes treatment based on CGM sensors.

Citations

Citations to this article as recorded by

Development of a Novel Insulin Sensor for Clinical Decision-Making
Eva Vargas, Eleonora M. Aiello, Jordan E. Pinsker, Hazhir Teymourian, Farshad Tehrani, Mei Mei Church, Lori M. Laffel, Francis J. Doyle, Mary-Elizabeth Patti, Eyal Dassau, Joseph Wang
Journal of Diabetes Science and Technology.2023; 17(4): 1029. CrossRef
Diabetes technology and sexual health: which role?
V. Zamponi, J. Haxhi, G. Pugliese, A. Faggiano, R. Mazzilli
Journal of Endocrinological Investigation.2023;[Epub] CrossRef
Discordance Between Glycated Hemoglobin A1c and the Glucose Management Indicator in People With Diabetes and Chronic Kidney Disease
Philippe Oriot, Claire Viry, Antoine Vandelaer, Sébastien Grigioni, Malanie Roy, Jean Christophe Philips, Gaëtan Prévost
Journal of Diabetes Science and Technology.2023; 17(6): 1553. CrossRef
Expertenaustausch zum Einsatz von kontinuierlichem Glukosemonitoring (CGM) im Diabetesmanagement: Eine aktuelle Bestandsaufnahme und Blick in die Zukunft
Andreas Thomas, Thomas Haak, Astrid Tombek, Bernhard Kulzer, Dominic Ehrmann, Olga Kordonouri, Jens Kroeger, Oliver Schubert-Olesen, Ralf Kolassa, Thorsten Siegmund, Nicola Haller, Lutz Heinemann
Diabetologie und Stoffwechsel.2023; 18(01): 57. CrossRef
Evaluation of the performance and usability of a novel continuous glucose monitoring system
Li Yan, Qiang Li, Qingbo Guan, Mingsong Han, Yu Zhao, Junfei Fang, Jiajun Zhao
International Journal of Diabetes in Developing Countries.2023; 43(4): 551. CrossRef
Efficacy of intermittent short‐term use of a real‐time continuous glucose monitoring system in non‐insulin–treated patients with type 2 diabetes: A randomized controlled trial
Sun Joon Moon, Kyung‐Soo Kim, Woo Je Lee, Mi Yeon Lee, Robert Vigersky, Cheol‐Young Park
Diabetes, Obesity and Metabolism.2023; 25(1): 110. CrossRef
Intermittent-scanned continuous glucose monitoring with low glucose alarms decreases hypoglycemia incidence in middle-aged adults with type 1 diabetes in real-life setting
Philippe Oriot, Michel P. Hermans
Journal of Diabetes and its Complications.2023; 37(2): 108385. CrossRef
Applications of Microwaves in Medicine
J.-C. Chiao, Changzhi Li, Jenshan Lin, Robert H. Caverly, James C. M. Hwang, Harel Rosen, Arye Rosen
IEEE Journal of Microwaves.2023; 3(1): 134. CrossRef
A Double-Needle Gold-Silver Electrodes Continuous Glucose Monitoring Device
C. Ben Ali Hassine, A. Tekin
IRBM.2023; 44(3): 100752. CrossRef
Accuracy of Flash Glucose Monitoring in Hemodialysis Patients With and Without Diabetes Mellitus
Michèle R. Weber, Matthias Diebold, Peter Wiesli, Andreas D. Kistler
Experimental and Clinical Endocrinology & Diabetes.2023; 131(03): 132. CrossRef
Minimally invasive electrochemical continuous glucose monitoring sensors: Recent progress and perspective
Yuanyuan Zou, Zhengkang Chu, Jiuchuan Guo, Shan Liu, Xing Ma, Jinhong Guo
Biosensors and Bioelectronics.2023; 225: 115103. CrossRef
Continuous Glucose Monitoring in Enterally Fed Children with Severe Central Nervous System Impairment
Marlena Górska, Joanna Kudzin, Anna Borkowska, Agnieszka Szlagatys-Sidorkiewicz, Agnieszka Szadkowska, Małgorzata Myśliwiec, Ewa Toporowska-Kowalska
Nutrients.2023; 15(3): 513. CrossRef
Prevalence of type 2 diabetes complications and its association with diet knowledge and skills and self‐care barriers in Tabriz, Iran: A cross‐sectional study
Habib Jalilian, Elnaz Javanshir, Leila Torkzadeh, Saeedeh Fehresti, Nazanin Mir, Majid Heidari‐Jamebozorgi, Somayeh Heydari
Health Science Reports.2023;[Epub] CrossRef
Status of continuous glucose monitoring use and management in tertiary hospitals of China: a cross-sectional study
Liping Chen, Xiaoqin Liu, Qin Lin, Hongmei Dai, Yong Zhao, Zumin Shi, Liping Wu
BMJ Open.2023; 13(2): e066801. CrossRef
Diboronic-Acid-Based Electrochemical Sensor for Enzyme-Free Selective and Sensitive Glucose Detection
Joong-Hyun Kim, Hongsik Choi, Chul-Soon Park, Heung-Seop Yim, Dongguk Kim, Sungmin Lee, Yeonkeong Lee
Biosensors.2023; 13(2): 248. CrossRef
Artificial intelligence biosensors for continuous glucose monitoring
Xiaofeng Jin, Andrew Cai, Tailin Xu, Xueji Zhang
Interdisciplinary Materials.2023; 2(2): 290. CrossRef
Continuous Glucose Monitoring in Dogs and Cats
Francesca Del Baldo, Federico Fracassi
Veterinary Clinics of North America: Small Animal Practice.2023; 53(3): 591. CrossRef
Accurate Post-Calibration Predictions for Noninvasive Glucose Measurements in People Using Confocal Raman Spectroscopy
Anders Pors, Kaspar G. Rasmussen, Rune Inglev, Nina Jendrike, Amalie Philipps, Ajenthen G. Ranjan, Vibe Vestergaard, Jan E. Henriksen, Kirsten Nørgaard, Guido Freckmann, Karl D. Hepp, Michael C. Gerstenberg, Anders Weber
ACS Sensors.2023; 8(3): 1272. CrossRef
Diabetes mellitus in der Akut- und Notfallmedizin
Leo Benning, Julian Krehl, Felix Patricius Hans
Notfallmedizin up2date.2023; 18(01): 45. CrossRef
Empowering People with Diabetes: Role of Continuous Glucose Monitor Systems
Sneha B Srivastava
American Journal of Lifestyle Medicine.2023; 17(3): 359. CrossRef
Diabétologie connectée : quelles sont les attentes des médecins et des patients ?
Nicolas Naïditch, Jean-Pierre Riveline
Médecine des Maladies Métaboliques.2023; 17(2): 2S3. CrossRef
Association of Vibrotactile Biofeedback With Reduced Ergonomic Risk for Surgeons During Tonsillectomy
Natalie A. Kelly, Abdulrahman Althubaiti, Aashika D. Katapadi, Adam G. Smith, Sarah C. Nyirjesy, Jane H. Yu, Amanda J. Onwuka, Tendy Chiang
JAMA Otolaryngology–Head & Neck Surgery.2023; 149(5): 397. CrossRef
The Evolution of Diabetes Technology – Options Toward Personalized Care
Maleeha Zahid, Samaneh Dowlatshahi, Abhishek H. Kansara, Archana R. Sadhu
Endocrine Practice.2023; 29(8): 653. CrossRef
A Personalized and Adaptive Insulin Bolus Calculator Based on Double Deep Q- Learning to Improve Type 1 Diabetes Management
Giulia Noaro, Taiyu Zhu, Giacomo Cappon, Andrea Facchinetti, Pantelis Georgiou
IEEE Journal of Biomedical and Health Informatics.2023; 27(5): 2536. CrossRef
Celebrating a Century of Insulin Discovery: A Critical Appraisal of the Emerging Alternative Insulin Delivery Systems
Ntethelelo Sibiya, Bonisiwe Mbatha, Phikelelani Ngubane, Andile Khathi
Current Drug Delivery.2023; 20(6): 656. CrossRef
Machine Learning–Based Time in Patterns for Blood Glucose Fluctuation Pattern Recognition in Type 1 Diabetes Management: Development and Validation Study
Nicholas Berin Chan, Weizi Li, Theingi Aung, Eghosa Bazuaye, Rosa M Montero
JMIR AI.2023; 2: e45450. CrossRef
Drug Delivery Systems for Personal Healthcare by Smart Wearable Patch System
Bikram Khadka, Byeongmoon Lee, Ki-Taek Kim
Biomolecules.2023; 13(6): 929. CrossRef
Wearable Electrochemical Glucose Sensors in Diabetes Management: A Comprehensive Review
Tamoghna Saha, Rafael Del Caño, Kuldeep Mahato, Ernesto De la Paz, Chuanrui Chen, Shichao Ding, Lu Yin, Joseph Wang
Chemical Reviews.2023; 123(12): 7854. CrossRef
Real-life 24-week changes in glycemic parameters among European users of flash glucose monitoring with type 1 and 2 diabetes and different levels of glycemic control
Annel Lameijer, Julia J. Bakker, Kalvin Kao, Yongjin Xu, Rijk O.B. Gans, Henk J.G. Bilo, Timothy C. Dunn, Peter R. van Dijk
Diabetes Research and Clinical Practice.2023; 201: 110735. CrossRef
Les médicaments anti-diabétiques : ce que le médecin anesthésiste réanimateur doit savoir
Michael Joubert
Anesthésie & Réanimation.2023; 9(3): 251. CrossRef
Glycemia control using remote technologies
L. A. Suplotova, O. O. Alieva
Meditsinskiy sovet = Medical Council.2023; 17(9): 81. CrossRef
Data-enabled learning and control algorithms for intelligent glucose management: The state of the art
Deheng Cai, Wenjing Wu, Marzia Cescon, Wei Liu, Linong Ji, Dawei Shi
Annual Reviews in Control.2023; 56: 100897. CrossRef
A Markov Model of Gap Occurrence in Continuous Glucose Monitoring Data for Realistic in Silico Clinical Trials
Martina Vettoretti, Martina Drecogna, Simone Del Favero, Andrea Facchinetti, Giovanni Sparacino
Computer Methods and Programs in Biomedicine.2023; 240: 107700. CrossRef
Volumetric Electron Transfer from Metabolites to Chemically Doped Polymer Electrodes
Siew Ting Melissa Tan, Gijun Lee, Kalee Rozylowicz, Adam Marks, Alberto Salleo
Advanced Functional Materials.2023;[Epub] CrossRef
Diabetes and hypertension MobileHealth systems: a review of general challenges and advancements
Bliss Utibe-Abasi Stephen, Benedicta C. Uzoewulu, Phillip Michael Asuquo, Simeon Ozuomba
Journal of Engineering and Applied Science.2023;[Epub] CrossRef
THE ASSESSMENT OF COMPENSATION OF CARBOHYDRATE METABOLISM IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH METABOLIC SYNDROME BEYOND THE LIMITS OF GLYCATED HEMOGLOBIN
Taras V. Romaniv, Nadiya V. Skrypnyk, Ulyana V. Synko, Nataliia M. Voronych-Semchenko, Oleh V. Melnyk, Anna O. Hryb, Igor B. Boruchok
Wiadomości Lekarskie.2023; 76(6): 1385. CrossRef
Pros and cons of continous glucose monitoring
Marcin Ciechański, Edyta Witkowska, Agnieszka Ostańska, Adrianna Szafran, Klaudia Wiśniewska, Laura Piasek, Grzegorz Godek, Kacper Więcław, Katarzyna Stańko, Wiktor Terelak
Journal of Medical Science.2023;[Epub] CrossRef
Continuous Glucose Monitoring by Insulin-Treated Pilots Flying Commercial Aircraft Within the ARA.MED.330 Diabetes Protocol: A Preliminary Feasibility Study
Gillian L. Garden, Fariba Shojaee-Moradie, Ewan J. Hutchison, Brian M. Frier, Kenneth M. Shaw, Simon R. Heller, Gerd Koehler, Julia K. Mader, Declan Maher, Graham A. Roberts, David L. Russell-Jones
Diabetes Technology & Therapeutics.2023; 25(8): 543. CrossRef
Importance of continuous glucose monitoring in the treatment of diabetes mellitus
Sun Joon Moon, Won-Young Lee
Journal of the Korean Medical Association.2023; 66(7): 432. CrossRef
DiaTrend: A dataset from advanced diabetes technology to enable development of novel analytic solutions
Temiloluwa Prioleau, Abigail Bartolome, Richard Comi, Catherine Stanger
Scientific Data.2023;[Epub] CrossRef
Testing the Real-World Accuracy of the Dexcom G6 Pro CGM During the Insulin-Only Bionic Pancreas Pivotal Trial
Martin Chase Marak, Peter Calhoun, Edward R. Damiano, Steven J. Russell, Katrina J. Ruedy, Roy W. Beck
Diabetes Technology & Therapeutics.2023; 25(11): 817. CrossRef
Use of continuous glucose monitoring in pediatric gastroenterology allows for personalized nutrition support care – Potential for collaboration between pediatric endocrinologists and gastroenterologists
Kathryn Hitchcock, Stephanie Oliveira
Journal of Pediatric Endocrinology and Diabetes.2023; 3: 34. CrossRef
Anti-biofouling strategies for implantable biosensors of continuous glucose monitoring systems
Yan Zheng, Dunyun Shi, Zheng Wang
Frontiers of Chemical Science and Engineering.2023;[Epub] CrossRef
A novel strategy for therapeutic drug monitoring: application of biosensors to quantify antimicrobials in biological matrices
Quanfang Wang, Sihan Li, Jiaojiao Chen, Luting Yang, Yulan Qiu, Qian Du, Chuhui Wang, Mengmeng Teng, Taotao Wang, Yalin Dong
Journal of Antimicrobial Chemotherapy.2023; 78(11): 2612. CrossRef
Hypoglycemic Effect of an Herbal Decoction (Modified Gangsimtang) in a Patient with Severe Type 2 Diabetes Mellitus Refusing Oral Anti-Diabetic Medication: A Case Report
Sungjun Joo, Hyonjun Chun, Jisu Lee, Seungmin Seo, Jungmin Lee, Jungtae Leem
Medicina.2023; 59(11): 1919. CrossRef
GluGAN: Generating Personalized Glucose Time Series Using Generative Adversarial Networks
Taiyu Zhu, Kezhi Li, Pau Herrero, Pantelis Georgiou
IEEE Journal of Biomedical and Health Informatics.2023; 27(10): 5122. CrossRef
Millifluidic valves and pumps made of tape and plastic
Josue U. Amador-Hernandez, Pablo E. Guevara-Pantoja, Diana F. Cedillo-Alcantar, Gabriel A. Caballero-Robledo, Jose L. Garcia-Cordero
Lab on a Chip.2023; 23(20): 4579. CrossRef
Continuous glucose monitoring metrics following sub-Tenon’s injection of triamcinolone acetonide for diabetic macular edema
Rei Sotani-Ogawa, Sentaro Kusuhara, Yushi Hirota, Kyung Woo Kim, Wataru Matsumiya, Wataru Ogawa, Makoto Nakamura
Graefe's Archive for Clinical and Experimental Ophthalmology.2023;[Epub] CrossRef
Offline Deep Reinforcement Learning and Off-Policy Evaluation for Personalized Basal Insulin Control in Type 1 Diabetes
Taiyu Zhu, Kezhi Li, Pantelis Georgiou
IEEE Journal of Biomedical and Health Informatics.2023; 27(10): 5087. CrossRef
Flash Glucose Monitoring in Croatia: The Optimal Number of Scans per Day to Achieve Good Glycemic Control in Type 1 Diabetes
Silvija Canecki-Varzic, Ivana Prpic-Krizevac, Maja Cigrovski Berkovic, Dario Rahelic, Ema Schonberger, Marina Gradiser, Ines Bilic-Curcic
Medicina.2023; 59(11): 1893. CrossRef
The importance of interpreting machine learning models for blood glucose prediction in diabetes: an analysis using SHAP
Francesco Prendin, Jacopo Pavan, Giacomo Cappon, Simone Del Favero, Giovanni Sparacino, Andrea Facchinetti
Scientific Reports.2023;[Epub] CrossRef
SHMAD: A Smart Health Care System to Monitor Alzheimer’s Disease Patients
Shabana R. Ziyad, May Altulyan, Meshal Alharbi
Journal of Alzheimer's Disease.2023; 95(4): 1545. CrossRef
Séquelles fonctionnelles après résection pancréatique carcinologique. Un sujet d’actualité pour les patients et les praticiens
Andrea Mulliri, Michael Joubert, Marie-Astrid Piquet, Arnaud Alves, Benoît Dupont
Journal de Chirurgie Viscérale.2023; 160(6): 470. CrossRef
Functional sequelae after pancreatic resection for cancer
Andrea Mulliri, Michael Joubert, Marie-Astrid Piquet, Arnaud Alves, Benoît Dupont
Journal of Visceral Surgery.2023;[Epub] CrossRef
Characteristics of glucose change in diabetes mellitus generalized through continuous wavelet transform processing: A preliminary study
Yoichi Nakamura, Shinya Furukawa
World Journal of Diabetes.2023; 14(10): 1562. CrossRef
Identifying and mapping measures of medication safety during transfer of care in a digital era: a scoping literature review
Catherine Leon, Helen Hogan, Yogini H Jani
BMJ Quality & Safety.2023; : bmjqs-2022-015859. CrossRef
Highly sensitive and stable glucose sensing using N-type conducting polymer based organic electrochemical transistor
Gang Zhou, Zhu Cao, Yangxuan Liu, Haoyu Zheng, Kai Xu
Journal of Electroanalytical Chemistry.2023; : 117961. CrossRef
A Prospective Multicenter Clinical Performance Evaluation of the C-CGM System
Mihailo Rebec, Kevin Cai, Ralph Dutt-Ballerstadt, Ellen Anderson
Journal of Diabetes Science and Technology.2022; 16(2): 390. CrossRef
Perceived Burdens and Benefits Associated With Continuous Glucose Monitor Use in Type 1 Diabetes Across the Lifespan
Vidita Divan, Margaret Greenfield, Christopher P. Morley, Ruth S. Weinstock
Journal of Diabetes Science and Technology.2022; 16(1): 88. CrossRef
Technologies for Diabetes Self-Monitoring: A Scoping Review and Assessment Using the REASSURED Criteria
Jessica Hanae Zafra-Tanaka, David Beran, Beatrice Vetter, Rangarajan Sampath, Antonio Bernabe-Ortiz
Journal of Diabetes Science and Technology.2022; 16(4): 962. CrossRef
Temporal Trends for Diabetes Management and Glycemic Control Between 2010 and 2019 in Korean Children and Adolescents with Type 1 Diabetes
Jaewon Choe, Seung Hyun Won, Yunsoo Choe, Sang Hee Park, Yun Jeong Lee, Jieun Lee, Young Ah Lee, Han Hyuk Lim, Jae-Ho Yoo, Seong Yong Lee, Eun Young Kim, Choong Ho Shin, Jae Hyun Kim
Diabetes Technology & Therapeutics.2022; 24(3): 201. CrossRef
International comparison of glycaemic control in people with type 1 diabetes: an update and extension
Regina Prigge, John A. McKnight, Sarah H. Wild, Aveni Haynes, Timothy W. Jones, Elizabeth A. Davis, Birgit Rami‐Merhar, Maria Fritsch, Christine Prchla, Astrid Lavens, Kris Doggen, Suchsia Chao, Ronnie Aronson, Ruth Brown, Else H. Ibfelt, Jannet Svensson,
Diabetic Medicine.2022;[Epub] CrossRef
Artificial intelligence perspective in the future of endocrine diseases
Mandana Hasanzad, Hamid Reza Aghaei Meybodi, Negar Sarhangi, Bagher Larijani
Journal of Diabetes & Metabolic Disorders.2022; 21(1): 971. CrossRef
Telehealth Technologies and Their Benefits to People With Diabetes
Chinenye O. Usoh, Kristine Kilen, Carolyn Keyes, Crystal Paige Johnson, Joseph A. Aloi
Diabetes Spectrum.2022; 35(1): 8. CrossRef
Acetylated Trifluoromethyl Diboronic Acid Anthracene with a Large Stokes Shift and Long Excitation Wavelength as a Glucose-Selective Probe
Hongsik Choi, Inhyeok Song, Chul Soon Park, Heung-seop Yim, Joong Hyun Kim
Applied Sciences.2022; 12(6): 2782. CrossRef
Suitability of the Unified Theory of Acceptance and Use of Technology 2 Model for Predicting mHealth Acceptance Using Diabetes as an Example: Qualitative Methods Triangulation Study
Patrik Schretzlmaier, Achim Hecker, Elske Ammenwerth
JMIR Human Factors.2022; 9(1): e34918. CrossRef
Continuous Glucose Monitoring System Based on Percutaneous Microneedle Array
Ming-Nan Chien, Yu-Jen Chen, Chin-Han Bai, Jung-Tung Huang
Micromachines.2022; 13(3): 478. CrossRef
Impact of COVID-19 Lockdown on the Metabolic Control Parameters in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis
Ifan Ali Wafa, Nando Reza Pratama, Nurizzah Farahiyah Sofia, Elsha Stephanie Anastasia, Tiffany Konstantin, Maharani Ayuputeri Wijaya, M. Rifqi Wiyono, Lilik Djuari, Hermina Novida
Diabetes & Metabolism Journal.2022; 46(2): 260. CrossRef
Expert Roundtable on Continuous Glucose Monitoring
Cheryl Rosenfeld, Thomas Blevins, Grazia Aleppo, Gregory Forlenza, Diana Isaacs, Javier Morales, Jane Seley, Jeffrey Unger
Endocrine Practice.2022; 28(6): 622. CrossRef
Glucose variability and predicted cardiovascular risk after gastrectomy
Jun Shibamoto, Takeshi Kubota, Takuma Ohashi, Hirotaka Konishi, Atsushi Shiozaki, Hitoshi Fujiwara, Kazuma Okamoto, Eigo Otsuji
Surgery Today.2022; 52(11): 1634. CrossRef
Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS
Tadej Battelino, Richard M Bergenstal, Angel Rodríguez, Laura Fernández Landó, Ross Bray, Zhentao Tong, Katelyn Brown
The Lancet Diabetes & Endocrinology.2022; 10(6): 407. CrossRef
Towards the Integration of an Islet-Based Biosensor in Closed-Loop Therapies for Patients With Type 1 Diabetes
Loïc Olçomendy, Louis Cassany, Antoine Pirog, Roberto Franco, Emilie Puginier, Manon Jaffredo, David Gucik-Derigny, Héctor Ríos, Alejandra Ferreira de Loza, Julien Gaitan, Matthieu Raoux, Yannick Bornat, Bogdan Catargi, Jochen Lang, David Henry, Sylvie Re
Frontiers in Endocrinology.2022;[Epub] CrossRef
Effect of divergent continuous glucose monitoring technologies on glycaemic control in type 1 diabetes mellitus: A systematic review and meta‐analysis of randomised controlled trials
Mona Elbalshy, Jillian Haszard, Hazel Smith, Sarahmarie Kuroko, Barbara Galland, Nick Oliver, Viral Shah, Martin I. de Bock, Benjamin J. Wheeler
Diabetic Medicine.2022;[Epub] CrossRef
Novel Glycemic Index Based on Continuous Glucose Monitoring to Predict Poor Clinical Outcomes in Critically Ill Patients: A Pilot Study
Eun Yeong Ha, Seung Min Chung, Il Rae Park, Yin Young Lee, Eun Young Choi, Jun Sung Moon
Frontiers in Endocrinology.2022;[Epub] CrossRef
Selection of Noninvasive Features in Wrist-Based Wearable Sensors to Predict Blood Glucose Concentrations Using Machine Learning Algorithms
Brian Bogue-Jimenez, Xiaolei Huang, Douglas Powell, Ana Doblas
Sensors.2022; 22(9): 3534. CrossRef
Generation of post-meal insulin correction boluses in type 1 diabetes simulation models for in-silico clinical trials: More realistic scenarios obtained using a decision tree approach
N. Camerlingo, M. Vettoretti, S. Del Favero, A. Facchinetti, P. Choudhary, G. Sparacino
Computer Methods and Programs in Biomedicine.2022; 221: 106862. CrossRef
A Miniaturized Optofluidic Glucose Monitoring System Based on Enzyme Colorimetry
Qingmei Xu, Chongwei Zou, Chengtao Sun, Xingguo Zhang, Haixia Yu, Dachao Li
IEEE Sensors Journal.2022; 22(10): 9246. CrossRef
Use and Trends of Diabetes Self-Management Technologies: A Correlation-Based Study
Jesús Fontecha, Iván González, Alfonso Barragán, Theodore Lim, Dario Pitocco
Journal of Diabetes Research.2022; 2022: 1. CrossRef
Nanotechnology in Diabetes Mellitus: Overview for Nurses
R Priya, Baba Vajrala
Pondicherry Journal of Nursing.2022; 15(1): 22. CrossRef
Effect of Different Glucose Monitoring Methods on Bold Glucose Control: A Systematic Review and Meta-Analysis
Yeling Wang, Congcong Zou, Han Na, Weixin Zeng, Xiaoyan Li, Xi Lou
Computational and Mathematical Methods in Medicine.2022; 2022: 1. CrossRef
Noninvasive Blood Glucose Monitoring Systems Using Near-Infrared Technology—A Review
Aminah Hina, Wala Saadeh
Sensors.2022; 22(13): 4855. CrossRef
Performance of islets of Langerhans conformally coated via an emulsion cross-linking method in diabetic rodents and nonhuman primates
Aaron A. Stock, Grisell C. Gonzalez, Sophia I. Pete, Teresa De Toni, Dora M. Berman, Alexander Rabassa, Waldo Diaz, James C. Geary, Melissa Willman, Joy M. Jackson, Noa H. DeHaseth, Noel M. Ziebarth, Anthony R. Hogan, Camillo Ricordi, Norma S. Kenyon, Ali
Science Advances.2022;[Epub] CrossRef
Review—Electrochemistry and Other Emerging Technologies for Continuous Glucose Monitoring Devices
Saroj Kumar Das, Kavya K. Nayak, P. R. Krishnaswamy, Vinay Kumar, Navakanta Bhat
ECS Sensors Plus.2022; 1(3): 031601. CrossRef
Design Strategies and Prospects in Developing Wearable Glucose Monitoring System Using Printable Organic Transistor and Microneedle: A Review
Fazliyatul Azwa Md Rezali, Norhayati Soin, Sharifah Fatmadiana Wan Muhamad Hatta, Mohamad Hazwan Mohd Daut, Muhammad Hafizuddin Al-Helmy Nouxman, Hanim Hussin
IEEE Sensors Journal.2022; 22(14): 13785. CrossRef
Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes
Armaan Nallicheri, Katherine M Mahoney, Hanna A Gutow, Natalie Bellini, Diana Isaacs
Endocrinology.2022; 18(1): 27. CrossRef
Evaluation of Mesoporous TiO2 Layers as Glucose Optical Sensors
David Ortiz de Zárate, Sara Serna, Salvador Ponce-Alcántara, Jaime García-Rupérez
Sensors.2022; 22(14): 5398. CrossRef
A Prospective Study on Continuous Glucose Monitoring in Glycogen Storage Disease Type Ia: Toward Glycemic Targets
Alessandro Rossi, Annieke Venema, Petra Haarsma, Lude Feldbrugge, Rob Burghard, David Rodriguez-Buritica, Giancarlo Parenti, Maaike H Oosterveer, Terry G J Derks
The Journal of Clinical Endocrinology & Metabolism.2022; 107(9): e3612. CrossRef
Continuous glucose monitoring as a close to real life alternative to meal studies – a pilot study with a functional drink containing amino acids and chromium
Azat Samigullin, Per M. Humpert, Elin Östman
Frontiers in Medical Technology.2022;[Epub] CrossRef
An overview of recent advances in insulin delivery and wearable technology for effective management of diabetes
Sujeet Kumar Raj, M. Ravindra Babu, Sukriti Vishwas, M.V.N.L. Chaitanya, Vancha Harish, Gaurav Gupta, Dinesh Kumar Chellappan, Kamal Dua, Sachin Kumar Singh
Journal of Drug Delivery Science and Technology.2022; 75: 103728. CrossRef
Medical Certification of Pilots Through the Insulin-Treated Diabetes Mellitus Protocol at the FAA
Lynn K. Stanwyck, James R. DeVoll, Joyce Pastore, Zykevise Gamble, Anna Poe, Gabrielle V. Gui
Aerospace Medicine and Human Performance.2022; 93(8): 627. CrossRef
Rate of glycaemic control and associated factors in patients with type 2 diabetes mellitus treated with insulin-based therapy at selected hospitals in Northwest Ethiopia: a multicentre cross-sectional study
Ashenafi Kibret Sendekie, Eyayaw Ashete Belachew, Ephrem Mebratu Dagnew, Adeladlew Kassie Netere
BMJ Open.2022; 12(9): e065250. CrossRef
Glucose Profiles Assessed by Intermittently Scanned Continuous Glucose Monitoring System during the Perioperative Period of Metabolic Surgery
Kyuho Kim, Sung Hee Choi, Hak Chul Jang, Young Suk Park, Tae Jung Oh
Diabetes & Metabolism Journal.2022; 46(5): 713. CrossRef
Hypoglycemic events and glycemic control effects between NPH and premixed insulin in patients with type 2 diabetes mellitus: A real-world experience at a comprehensive specialized hospital in Ethiopia
Ashenafi Kibret Sendekie, Adeladlew Kassie Netere, Eyayaw Ashete Belachew, Rekha Samuel
PLOS ONE.2022; 17(9): e0275032. CrossRef
Continuous Glucose Monitoring for the Diagnosis of Gestational Diabetes Mellitus: A Pilot Study
Daria Di Filippo, Marrwah Ahmadzai, Melissa Han Yiin Chang, Ksana Horgan, Ru Min Ong, Justine Darling, Mahmood Akhtar, Amanda Henry, Alec Welsh, Daniela Foti
Journal of Diabetes Research.2022; 2022: 1. CrossRef
Caring for people with diabetes
Martha M. Funnell, Katherine A. Kloss, Robin B. Nwankwo
Nursing.2022; 52(11): 26. CrossRef
Tackling the challenges of developing microneedle-based electrochemical sensors
Hilmee Abdullah, Tonghathai Phairatana, Itthipon Jeerapan
Microchimica Acta.2022;[Epub] CrossRef
A Concise and Systematic Review on Non-Invasive Glucose Monitoring for Potential Diabetes Management
Soumyasanta Laha, Aditi Rajput, Suvra S. Laha, Rohan Jadhav
Biosensors.2022; 12(11): 965. CrossRef
Assessment of Seasonal Stochastic Local Models for Glucose Prediction without Meal Size Information under Free-Living Conditions
Francesco Prendin, José-Luis Díez, Simone Del Favero, Giovanni Sparacino, Andrea Facchinetti, Jorge Bondia
Sensors.2022; 22(22): 8682. CrossRef
Wearable Sensor-Based Monitoring of Environmental Exposures and the Associated Health Effects: A Review
Xueer Lin, Jiaying Luo, Minyan Liao, Yalan Su, Mo Lv, Qing Li, Shenglan Xiao, Jianbang Xiang
Biosensors.2022; 12(12): 1131. CrossRef
Acceptability and feasibility of continuous glucose monitoring in people with diabetes: protocol for a mixed-methods systematic review of quantitative and qualitative evidence
Jennifer V. E. Brown, Ramzi Ajjan, Najma Siddiqi, Peter A. Coventry
Systematic Reviews.2022;[Epub] CrossRef
Utilization of Personalized Machine-Learning to Screen for Dysglycemia from Ambulatory ECG, toward Noninvasive Blood Glucose Monitoring
I-Min Chiu, Chi-Yung Cheng, Po-Kai Chang, Chao-Jui Li, Fu-Jen Cheng, Chun-Hung Richard Lin
Biosensors.2022; 13(1): 23. CrossRef
Effect of hydroxychloroquine on glycemic variability in type 2 diabetes patients uncontrolled on glimepiride and metformin therapy
Rajesh Rajput, Suyasha Saini, Siddhant Rajput, Parankush Upadhyay
Indian Journal of Endocrinology and Metabolism.2022; 26(6): 537. CrossRef
GESTATIONAL DIABETES MELLITUS: MODERN GLYCEMIA MONITORING SYSTEMS
YU.A. DUDAREVA, V.A. GURYEVA, G.V. NEMTSEVA
AVICENNA BULLETIN.2022; 24(1): 97. CrossRef
Extraction With Sweat-Sebum Emulsion as a New Test Method for Leachables in Patch-Based Medical Devices, Illustrated by Assessment of Isobornylacrylate (IBOA) in Diabetes Products
Herbert Fink, Nuno M. de Barros Fernandes, Jörg Weissmann, Manfred Frey
Journal of Diabetes Science and Technology.2021; 15(4): 792. CrossRef
Mathematical Models of Meal Amount and Timing Variability With Implementation in the Type-1 Diabetes Patient Decision Simulator
Nunzio Camerlingo, Martina Vettoretti, Simone Del Favero, Andrea Facchinetti, Giovanni Sparacino
Journal of Diabetes Science and Technology.2021; 15(2): 346. CrossRef
Fit‐for‐Purpose Biometric Monitoring Technologies: Leveraging the Laboratory Biomarker Experience
Alan Godfrey, Benjamin Vandendriessche, Jessie P. Bakker, Cheryl Fitzer‐Attas, Ninad Gujar, Matthew Hobbs, Qi Liu, Carrie A. Northcott, Virginia Parks, William A. Wood, Vadim Zipunnikov, John A. Wagner, Elena S. Izmailova
Clinical and Translational Science.2021; 14(1): 62. CrossRef
Self-charging wearables for continuous health monitoring
Jiyong Kim, Salman Khan, Peng Wu, Sungjin Park, Hwanjoo Park, Choongho Yu, Woochul Kim
Nano Energy.2021; 79: 105419. CrossRef
Impact of Switching from Intermittently Scanned to Real-Time Continuous Glucose Monitoring Systems in a Type 1 Diabetes Patient French Cohort: An Observational Study of Clinical Practices
Yannis Préau, Martine Armand, Sébastien Galie, Pauline Schaepelynck, Denis Raccah
Diabetes Technology & Therapeutics.2021; 23(4): 259. CrossRef
Individualizing Time-in-Range Goals in Management of Diabetes Mellitus and Role of Insulin: Clinical Insights From a Multinational Panel
Sanjay Kalra, Shehla Shaikh, Gagan Priya, Manas P. Baruah, Abhyudaya Verma, Ashok K. Das, Mona Shah, Sambit Das, Deepak Khandelwal, Debmalya Sanyal, Sujoy Ghosh, Banshi Saboo, Ganapathi Bantwal, Usha Ayyagari, Daphne Gardner, Cecilia Jimeno, Nancy E. Barb
Diabetes Therapy.2021; 12(2): 465. CrossRef
Machine-Learning Based Model to Improve Insulin Bolus Calculation in Type 1 Diabetes Therapy
Giulia Noaro, Giacomo Cappon, Martina Vettoretti, Giovanni Sparacino, Simone Del Favero, Andrea Facchinetti
IEEE Transactions on Biomedical Engineering.2021; 68(1): 247. CrossRef
Efficacy of telemedicine for persons with type 1 diabetes during Covid19 lockdown
Federico Boscari, Sara Ferretto, Ambra Uliana, Angelo Avogaro, Daniela Bruttomesso
Nutrition & Diabetes.2021;[Epub] CrossRef
Technological innovation of Continuous Glucose Monitoring (CGM) as a tool for commercial aviation pilots with insulin-treated diabetes and stakeholders/regulators: A new chance to improve the directives?
F. Strollo, A. Furia, P. Verde, A. Bellia, M. Grussu, A. Mambro, M.D. Petrelli, S. Gentile
Diabetes Research and Clinical Practice.2021; 172: 108638. CrossRef
Machine Learning Techniques for Hypoglycemia Prediction: Trends and Challenges
Omer Mujahid, Ivan Contreras, Josep Vehi
Sensors.2021; 21(2): 546. CrossRef
Time in range–A1c hemoglobin relationship in continuous glucose monitoring of type 1 diabetes: a real-world study
Marina Valenzano, Ivan Cibrario Bertolotti, Adriano Valenzano, Giorgio Grassi
BMJ Open Diabetes Research & Care.2021; 9(1): e001045. CrossRef
Machine learning for the diagnosis of early-stage diabetes using temporal glucose profiles
Woo Seok Lee, Junghyo Jo, Taegeun Song
Journal of the Korean Physical Society.2021; 78(5): 373. CrossRef
Forecasting of Glucose Levels and Hypoglycemic Events: Head-to-Head Comparison of Linear and Nonlinear Data-Driven Algorithms Based on Continuous Glucose Monitoring Data Only
Francesco Prendin, Simone Del Favero, Martina Vettoretti, Giovanni Sparacino, Andrea Facchinetti
Sensors.2021; 21(5): 1647. CrossRef
A “Slide Rule” to Adjust Insulin Dose Using Trend Arrows in Adults with Type 1 Diabetes: Test in Silico and in Real Life
Daniela Bruttomesso, Federico Boscari, Giuseppe Lepore, Giulia Noaro, Giacomo Cappon, Angela Girelli, Lutgarda Bozzetto, Andrea Tumminia, Giorgio Grassi, Giovanni Sparacino, Luigi Laviola, Andrea Facchinetti
Diabetes Therapy.2021; 12(5): 1313. CrossRef
Glycemic variability and cardiovascular disease in patients with type 2 diabetes
Marcela Martinez, Jimena Santamarina, Adrian Pavesi, Carla Musso, Guillermo E Umpierrez
BMJ Open Diabetes Research & Care.2021; 9(1): e002032. CrossRef
Hypoglycaemia detection and prediction techniques: A systematic review on the latest developments
Omar Diouri, Monika Cigler, Martina Vettoretti, Julia K. Mader, Pratik Choudhary, Eric Renard
Diabetes/Metabolism Research and Reviews.2021;[Epub] CrossRef
Smartphone-based colorimetric detection systems for glucose monitoring in the diagnosis and management of diabetes
Özlem Kap, Volkan Kılıç, John G. Hardy, Nesrin Horzum
The Analyst.2021; 146(9): 2784. CrossRef
The impact of hypoglycaemia on the quality of life of family members of adults with type 1 or type 2 diabetes: A qualitative systematic review
Mette Valdersdorf Jensen, Melanie Broadley, Jane Speight, Alison Scope, Louise Preston, Simon Heller, Bastiaan E. de Galan, Frans Pouwer, Christel Hendrieckx
Diabetic Medicine.2021;[Epub] CrossRef
A review of biosensor technology and algorithms for glucose monitoring
Yaguang Zhang, Jingxue Sun, Liansheng Liu, Hong Qiao
Journal of Diabetes and its Complications.2021; 35(8): 107929. CrossRef
Optical glucose biosensor built-in disposable strips and wearable electronic devices
Abdullah Reda, Sherif A. El-Safty, Mahmoud M. Selim, Mohamed A. Shenashen
Biosensors and Bioelectronics.2021; 185: 113237. CrossRef
Advances, Challenges, and Cost Associated with Continuous Glucose Monitor Use in Adolescents and Young Adults with Type 1 Diabetes
Karishma A. Datye, Daniel R. Tilden, Angelee M. Parmar, Eveline R. Goethals, Sarah S. Jaser
Current Diabetes Reports.2021;[Epub] CrossRef
Is HbA1c an ideal biomarker of well-controlled diabetes?
Georgia Kaiafa, Stavroula Veneti, George Polychronopoulos, Dimitrios Pilalas, Stylianos Daios, Ilias Kanellos, Triantafyllos Didangelos, Stamatina Pagoni, Christos Savopoulos
Postgraduate Medical Journal.2021; 97(1148): 380. CrossRef
Technology in the management of type 2 diabetes: Present status and future prospects
Aideen Daly, Roman Hovorka
Diabetes, Obesity and Metabolism.2021; 23(8): 1722. CrossRef
A Non-Invasive Flexible Glucose Monitoring Sensor Using a Broadband Reject Filter
Moussa Bteich, Jessica Hanna, Joseph Costantine, Rouwaida Kanj, Youssef Tawk, Ali H. Ramadan, Assaad A. Eid
IEEE Journal of Electromagnetics, RF and Microwaves in Medicine and Biology.2021; 5(2): 139. CrossRef
Wearable patch delivery system for artificial pancreas health diagnostic-therapeutic application: A review
Nur Farrahain Nadia Ahmad, Nik Nazri Nik Ghazali, Yew Hoong Wong
Biosensors and Bioelectronics.2021; 189: 113384. CrossRef
Technological Ecological Momentary Assessment Tools to Study Type 1 Diabetes in Youth: Viewpoint of Methodologies
Mary Katherine Ray, Alana McMichael, Maria Rivera-Santana, Jacob Noel, Tamara Hershey
JMIR Diabetes.2021; 6(2): e27027. CrossRef
Designing biomaterials for the modulation of allogeneic and autoimmune responses to cellular implants in Type 1 Diabetes
Magdalena M. Samojlik, Cherie L. Stabler
Acta Biomaterialia.2021; 133: 87. CrossRef
Evaluation of a continuous glucose monitoring system in neonatal foals
David Wong, Caitlin Malik, Katarzyna Dembek, Krista Estell, Megan Marchitello, Katie Wilson
Journal of Veterinary Internal Medicine.2021; 35(4): 1995. CrossRef
Flash Glucose Monitoring in the Netherlands: Increased monitoring frequency is associated with improvement of glycemic parameters
Annel Lameijer, Nicole Lommerde, Timothy C. Dunn, Marion J. Fokkert, Mireille A. Edens, Kalvin Kao, Yongjin Xu, R.O.B. Gans, Henk J.G. Bilo, Peter R. van Dijk
Diabetes Research and Clinical Practice.2021; 177: 108897. CrossRef
Utilisation, access and recommendations regarding technologies for people living with type 1 diabetes: consensus statement of the ADS/ADEA/APEG/ADIPS Working Group
Anthony J Pease, Sofianos Andrikopoulos, Mary B Abraham, Maria E Craig, Brett Fenton, Jane Overland, Sarah Price, David Simmons, Glynis P Ross
Medical Journal of Australia.2021; 215(10): 473. CrossRef
Catalytic effects of magnetic and conductive nanoparticles on immobilized glucose oxidase in skin sensors
Lilian C Alarcón-Segovia, Amay J Bandodkar, John A Rogers, Ignacio Rintoul
Nanotechnology.2021; 32(37): 375101. CrossRef
Optical Glucose Sensor Using Pressure Sensitive Paint
Jongwon Park
Sensors.2021; 21(13): 4474. CrossRef
Type 1 diabetes glycemic management: Insulin therapy, glucose monitoring, and automation
Bruce A. Perkins, Jennifer L. Sherr, Chantal Mathieu
Science.2021; 373(6554): 522. CrossRef
Clinical Utilities of Continuous Glucose Monitoring and Insulin Pumps in Pediatric Patients with Type 1 Diabetes
Jieun Lee, Jae Hyun Kim
The Ewha Medical Journal.2021; 44(3): 55. CrossRef
Personalized Postprandial Glucose Response–Targeting Diet Versus Mediterranean Diet for Glycemic Control in Prediabetes
Orly Ben-Yacov, Anastasia Godneva, Michal Rein, Smadar Shilo, Dmitry Kolobkov, Netta Koren, Noa Cohen Dolev, Tamara Travinsky Shmul, Bat Chen Wolf, Noa Kosower, Keren Sagiv, Maya Lotan-Pompan, Niv Zmora, Adina Weinberger, Eran Elinav, Eran Segal
Diabetes Care.2021; 44(9): 1980. CrossRef
Lack of Acceptance of Digital Healthcare in the Medical Market: Addressing Old Problems Raised by Various Clinical Professionals and Developing Possible Solutions
Jong Il Park, Hwa Young Lee, Hyunah Kim, Jisan Lee, Jiwon Shinn, Hun-Sung Kim
Journal of Korean Medical Science.2021;[Epub] CrossRef
Benefits of a Switch from Intermittently Scanned Continuous Glucose Monitoring (isCGM) to Real-Time (rt) CGM in Diabetes Type 1 Suboptimal Controlled Patients in Real-Life: A One-Year Prospective Study §
Yannis Préau, Sébastien Galie, Pauline Schaepelynck, Martine Armand, Denis Raccah
Sensors.2021; 21(18): 6131. CrossRef
A Hybrid Automata Approach for Monitoring the Patient in the Loop in Artificial Pancreas Systems
Aleix Beneyto, Vicenç Puig, B. Wayne Bequette, Josep Vehi
Sensors.2021; 21(21): 7117. CrossRef
Editors’ Choice—Review—From Polarography to Electrochemical Biosensors: The 100-Year Quest for Selectivity and Sensitivity
William R. Heineman, Peter T. Kissinger, Kenneth R. Wehmeyer
Journal of The Electrochemical Society.2021; 168(11): 116504. CrossRef
Digital health and diabetes: experience from India
Jothydev Kesavadev, Gopika Krishnan, Viswanathan Mohan
Therapeutic Advances in Endocrinology and Metabolism.2021; 12: 204201882110546. CrossRef
Current Advances of Artificial Pancreas Systems: A Comprehensive Review of the Clinical Evidence
Sun Joon Moon, Inha Jung, Cheol-Young Park
Diabetes & Metabolism Journal.2021; 45(6): 813. CrossRef
Factors Associated with Adherence to Self-Monitoring of Blood Glucose Among Young People with Type 1 Diabetes in China: A Cross-Sectional Study
Wencong Lv, Jiaxin Luo, Qing Long, Jundi Yang, Xin Wang, Jia Guo
Patient Preference and Adherence.2021; Volume 15: 2809. CrossRef
Continuous glucose monitoring devices: A brief presentation (Review)
Doina Mihai, Diana Stefan, Daniela Stegaru, Georgiana Bernea, Ileana Vacaroiu, Toma Papacocea, Mircea Lupușoru, Adriana Nica, Ovidiu Stiru, Dorin Dragos, Octavian Olaru
Experimental and Therapeutic Medicine.2021;[Epub] CrossRef
Acute glycemic variability on admission predicts the prognosis in hospitalized patients with coronary artery disease: a meta-analysis
Zhaokun Pu, Lihong Lai, Xishan Yang, Yanyu Wang, Pingshuan Dong, Dan Wang, Yingli Xie, Zesen Han
Endocrine.2020; 67(3): 526. CrossRef
Glycemic profile of women with normoglycemia and gestational diabetes mellitus during early pregnancy using continuous glucose monitoring system
Charandeep Singh, Yashdeep Gupta, Alpesh Goyal, Mani Kalaivani, Vineeta Garg, Juhi Bharti, Seema Singhal, Garima Kachhawa, Vidushi Kulshrestha, Rajesh Kumari, Reeta Mahey, Jai B Sharma, Neerja Bhatla, Rajesh Khadgawat, Nandita Gupta, Nikhil Tandon
Diabetes Research and Clinical Practice.2020; 169: 108409. CrossRef
Efficacy of Intermittently Scanned Continuous Glucose Monitoring in the Prevention of Recurrent Severe Hypoglycemia
Timothy M.E. Davis, Penny Dwyer, Michelle England, P. Gerry Fegan, Wendy A. Davis
Diabetes Technology & Therapeutics.2020; 22(5): 367. CrossRef
How was the Diabetes Metabolism Journal added to MEDLINE?
Hye Jin Yoo
Science Editing.2020; 7(2): 201. CrossRef
Applying Nanomaterials to Modern Biomedical Electrochemical Detection of Metabolites, Electrolytes, and Pathogens
Itthipon Jeerapan, Thitaporn Sonsa-ard, Duangjai Nacapricha
Chemosensors.2020; 8(3): 71. CrossRef
Clinical Opportunities for Continuous Biosensing and Closed-Loop Therapies
Jason Li, Jia Y. Liang, Steven J. Laken, Robert Langer, Giovanni Traverso
Trends in Chemistry.2020; 2(4): 319. CrossRef
A single-blind, randomised, crossover study to reduce hypoglycaemia risk during postprandial exercise with closed-loop insulin delivery in adults with type 1 diabetes: announced (with or without bolus reduction) vs unannounced exercise strategies
Sémah Tagougui, Nadine Taleb, Laurent Legault, Corinne Suppère, Virginie Messier, Inès Boukabous, Azadeh Shohoudi, Martin Ladouceur, Rémi Rabasa-Lhoret
Diabetologia.2020; 63(11): 2282. CrossRef
Bimetallic PtAu alloy nanomaterials for nonenzymatic selective glucose sensing at low potential
Lingling Lin, Shaohuang Weng, Yanjie Zheng, Xiyao Liu, Shaoming Ying, Feng Chen, Donghong You
Journal of Electroanalytical Chemistry.2020; 865: 114147. CrossRef
Type 1 Diabetes in Youth and Technology-Based Advances in Management
Christopher Ferber, Catherine S. Mao, Jennifer K. Yee
Advances in Pediatrics.2020; 67: 73. CrossRef
Advanced Diabetes Management Using Artificial Intelligence and Continuous Glucose Monitoring Sensors
Martina Vettoretti, Giacomo Cappon, Andrea Facchinetti, Giovanni Sparacino
Sensors.2020; 20(14): 3870. CrossRef
Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, active‐controlled, randomized, double‐blind study with open‐label extension (the EVERGREEN study)
Gyuri Kim, Soo Lim, Hyuk‐Sang Kwon, Ie B. Park, Kyu J. Ahn, Cheol‐Young Park, Su K. Kwon, Hye S. Kim, Seok W. Park, Sin G. Kim, Min K. Moon, Eun S. Kim, Choon H. Chung, Kang S. Park, Mikyung Kim, Dong J. Chung, Chang B. Lee, Tae H. Kim, Moon‐Kyu Lee
Diabetes, Obesity and Metabolism.2020; 22(9): 1527. CrossRef
Association Between Continuous Glucose Monitoring-Derived Time in Range, Other Core Metrics, and Albuminuria in Type 2 Diabetes
Jee Hee Yoo, Min Sun Choi, Jiyeon Ahn, Sung Woon Park, Yejin Kim, Kyu Yeon Hur, Sang-Man Jin, Gyuri Kim, Jae Hyeon Kim
Diabetes Technology & Therapeutics.2020; 22(10): 768. CrossRef
A New Approach to Determining Liquid Concentration Using Multiband Annular Ring Microwave Sensor and Polarity Correlator
Waleed Sethi, Ahmed Ibrahim, Khaled Issa, Ali Albishi, Saleh Alshebeili
Electronics.2020; 9(10): 1616. CrossRef
Estrategia terapéutica en el paciente diabético (I). Empoderamiento del paciente y formación. Objetivos terapéuticos. Estilo de vida, alimentación, vacunación y consejos al paciente diabético
F.B. Rivas Sánchez, J. Sanz Cánovas, J. Martín Carmona, S. Jansen Chaparro
Medicine - Programa de Formación Médica Continuada Acreditado.2020; 13(17): 943. CrossRef
Current status of continuous glucose monitoring among Korean children and adolescents with type 1 diabetes mellitus
Jae Hyun Kim
Annals of Pediatric Endocrinology & Metabolism.2020; 25(3): 145. CrossRef
Towards sensor-based calving detection in the rangelands: a systematic review of credible behavioral and physiological indicators
Anita Z Chang, David L Swain, Mark G Trotter
Translational Animal Science.2020;[Epub] CrossRef
Electrochemical glucose sensors in diabetes management: an updated review (2010–2020)
Hazhir Teymourian, Abbas Barfidokht, Joseph Wang
Chemical Society Reviews.2020; 49(21): 7671. CrossRef
An analytical approach to determine the optimal duration of continuous glucose monitoring data required to reliably estimate time in hypoglycemia
Nunzio Camerlingo, Martina Vettoretti, Andrea Facchinetti, Giovanni Sparacino, Julia K. Mader, Pratik Choudhary, Simone Del Favero
Scientific Reports.2020;[Epub] CrossRef
Smartphone-Based Data Collection in Ophthalmology
Florian Philipp Raber, Rokas Gerbutavicius, Armin Wolf, Karsten Kortüm
Klinische Monatsblätter für Augenheilkunde.2020; 237(12): 1420. CrossRef
Glycemic Status Assessment by the Latest Glucose Monitoring Technologies
Ilaria Malandrucco, Benedetta Russo, Fabiana Picconi, Marika Menduni, Simona Frontoni
International Journal of Molecular Sciences.2020; 21(21): 8243. CrossRef
Medical Nutrition Therapy Using Continuous Glucose Monitoring System
Mee Ra Kweon
The Journal of Korean Diabetes.2020; 21(4): 216. CrossRef
Use of Flash Glucose Monitoring in Patients on Intensive Insulin Treatment
Jun Sung Moon
The Journal of Korean Diabetes.2020; 21(4): 184. CrossRef
Data Analysis and Accuracy Evaluation of a Continuous Glucose-Monitoring Device
Lijun Cai, Wancheng Ge, Zhigang Zhu, Xueling Zhao, Zhanhong Li
Journal of Sensors.2019; 2019: 1. CrossRef
Development of an Error Model for a Factory-Calibrated Continuous Glucose Monitoring Sensor with 10-Day Lifetime
Martina Vettoretti, Cristina Battocchio, Giovanni Sparacino, Andrea Facchinetti
Sensors.2019; 19(23): 5320. CrossRef

Original Articles

Clinical Diabetes & Therapeutics
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice: A Ram Hong, Bo Kyung Koo, Sang Wan Kim, Ka Hee Yi, Min Kyong Moon; Diabetes Metab J. 2019;43(5):590-606. Published online February 28, 2019; DOI: https://doi.org/10.4093/dmj.2018.0134

6,187 View
93 Download
17 Citations

Abstract PDF Supplementary Material PubReader

Background

This study aimed to evaluate the efficacy and safety of sodium-glucose cotransporter-2 (SGLT2) inhibitors in Korean patients who had inadequately controlled type 2 diabetes mellitus (T2DM) in real-world clinical practice.

Methods

We included 410 patients who started SGLT2 inhibitors (empagliflozin or dapagliflozin) as add-on therapy or switch therapy between February 2015 and June 2017. The primary efficacy endpoint was a change in glycosylated hemoglobin (HbA1c) from baseline to week 12. The secondary endpoints were patients achieving HbA1c <7.0% and changes in the fasting plasma glucose (FPG), lipid profiles, body weight, and blood pressure (BP).

Results

The mean HbA1c at baseline was 8.5% (8.6% in the add-on group and 8.4% in the switch group). At week 12, the mean adjusted HbA1c decreased by −0.68% in the overall patients (P<0.001), by −0.94% in the add-on group, and by −0.42% in the switch group. Significant reductions in FPG were also observed both in the add-on group and switch group (−30.3 and −19.8 mg/dL, respectively). Serum triglyceride (−16.5 mg/dL), body weight (−2.1 kg), systolic BP (−4.7 mm Hg), and diastolic BP (−1.3 mm Hg) were significantly improved in the overall patients. Approximately 18.3% of the patients achieved HbA1c <7.0% at week 12. A low incidence of hypoglycemia and genital tract infection was observed (6.3% and 2.2%, respectively).

Conclusion

SGLT2 inhibitors can be a suitable option as either add-on or switch therapy for Korean patients with inadequately controlled T2DM.

Citations

Citations to this article as recorded by

Real-world assessment of effectiveness and safety profile of remogliflozin etabonate in management of type 2 diabetes mellitus
Bipin Sethi, Subhankar Chowdhury, Supratik Bhattacharya, Sagar Katare, Sachin Suryawanshi, Hanmant Barkate
International Journal of Diabetes in Developing Countries.2023; 43(2): 214. CrossRef
Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: The BEYOND study
Hyeong Kyu Park, Kyoung‐Ah Kim, Kyung‐Wan Min, Tae‐Seo Sohn, In Kyung Jeong, Chul Woo Ahn, Nan‐Hee Kim, Ie Byung Park, Ho Chan Cho, Choon Hee Chung, Sung Hee Choi, Kang Seo Park, Seoung‐Oh Yang, Kwan Woo Lee
Diabetes, Obesity and Metabolism.2023; 25(9): 2743. CrossRef
Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study
Satilmis Bilgin, Ozge Kurtkulagi, Tuba Taslamacioglu Duman, Burcin Meryem Atak Tel, Gizem Kahveci, Murat Kiran, Eray Erge, Gulali Aktas
Irish Journal of Medical Science (1971 -).2022; 191(4): 1647. CrossRef
Efficacy and Safety of Empagliflozin as Add-On Therapy in Patients of Type-2 Diabetes Mellitus
Nauman Wazir, Shafqat Ur Rehman
Journal of Gandhara Medical and Dental Science.2022; 9(1): 24. CrossRef
Five comparative cohorts to assess the risk of genital tract infections associated with sodium‐glucose cotransporter‐2 inhibitors initiation in type 2 diabetes mellitus
Wajd Alkabbani, Arsène Zongo, Jasjeet K. Minhas‐Sandhu, Dean T. Eurich, Baiju R. Shah, Mhd. Wasem Alsabbagh, John‐Michael Gamble
Diabetic Medicine.2022;[Epub] CrossRef
Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice
Da Hea Seo, Young Ju Suh, Yongin Cho, Seong Hee Ahn, Seongha Seo, Seongbin Hong, Yong-ho Lee, Young Ju Choi, Eunjig Lee, So Hun Kim
Yonsei Medical Journal.2022; 63(9): 825. CrossRef
Using real-world data for supporting regulatory decision making: Comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data
Ha Young Jang, In-Wha Kim, Jung Mi Oh
Frontiers in Pharmacology.2022;[Epub] CrossRef
Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin
Ai-Yu Yang, Hung-Chun Chen
International Journal of Clinical Pharmacy.2021; 43(4): 1015. CrossRef
Empagliflozin Regulates the AdipoR1/p-AMPK/p-ACC Pathway to Alleviate Lipid Deposition in Diabetic Nephropathy
Zhiqin Zhang, Lihua Ni, Lian Zhang, Dongqing Zha, Chun Hu, Lingli Zhang, Huiling Feng, Xiaobao Wei, Xiaoyan Wu
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 227. CrossRef
Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial
Hiroaki Seino
Diabetes Therapy.2021; 12(3): 863. CrossRef
Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Retinal Vein Occlusion Among Patients With Type 2 Diabetes: A Propensity Score–Matched Cohort Study
Min-Kyung Lee, Bongsung Kim, Kyungdo Han, Jae-Hyuk Lee, Minhee Kim, Mee Kyoung Kim, Ki-Hyun Baek, Ki-Ho Song, Hyuk-Sang Kwon, Young-Jung Roh
Diabetes Care.2021; 44(10): 2419. CrossRef
Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians
Muhammad Afzal, Fahad Al-Abbasi, Muhammad Nadeem, Sultan Alshehri, Mohammed Ghoneim, Syed Imam, Waleed Almalki, Imran Kazmi
Metabolites.2021; 11(11): 794. CrossRef
Sodium-Glucose Cotransporter-2 Inhibitor for Renal Function Preservation in Patients with Type 2 Diabetes Mellitus: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement
Tae Jung Oh, Ju-Young Moon, Kyu Yeon Hur, Seung Hyun Ko, Hyun Jung Kim, Taehee Kim, Dong Won Lee, Min Kyong Moon
Diabetes & Metabolism Journal.2020; 44(4): 489. CrossRef
Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: A Korean Diabetes Association and Korean Society of Nephrology consensus statement
Tae Jung Oh, Ju-Young Moon, Kyu Yeon Hur, Seung Hyun Ko, Hyun Jung Kim, Taehee Kim, Dong Won Lee, Min Kyong Moon
Kidney Research and Clinical Practice.2020; 39(3): 269. CrossRef
Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan
Jung-Fu Chen, Yun-Shing Peng, Chung-Sen Chen, Chin-Hsiao Tseng, Pei-Chi Chen, Ting-I Lee, Yung-Chuan Lu, Yi-Sun Yang, Ching-Ling Lin, Yi-Jen Hung, Szu-Ta Chen, Chieh-Hsiang Lu, Chwen-Yi Yang, Ching-Chu Chen, Chun-Chuan Lee, Pi-Jung Hsiao, Ju-Ying Jiang, S
PeerJ.2020; 8: e9998. CrossRef
Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus
Maria Mirabelli, Eusebio Chiefari, Patrizia Caroleo, Raffaella Vero, Francesco Saverio Brunetti, Domenica Maria Corigliano, Biagio Arcidiacono, Daniela Patrizia Foti, Luigi Puccio, Antonio Brunetti
Journal of Diabetes Research.2019; 2019: 1. CrossRef
An Age of Sodium-Glucose Cotransporter-2 Inhibitor Priority: Are We Ready?
Ji A Seo
Diabetes & Metabolism Journal.2019; 43(5): 578. CrossRef

Clinical Care/Education
Patient Understanding of Hypoglycemia in Tertiary Referral Centers: Nan Hee Cho, Nam Kyung Kim, Eugene Han, Jun Hwa Hong, Eon Ju Jeon, Jun Sung Moon, Mi Hae Seo, Ji Eun Lee, Hyun-Ae Seo, Mi-Kyung Kim, Hye Soon Kim; Diabetes Metab J. 2018;42(1):43-52. Published online February 23, 2018; DOI: https://doi.org/10.4093/dmj.2018.42.1.43

4,071 View
51 Download
5 Citations

Abstract PDF PubReader

Background

Hypoglycemia is an important complication in the treatment of patients with diabetes. We surveyed the insight by patients with diabetes into hypoglycemia, their hypoglycemia avoidance behavior, and their level of worry regarding hypoglycemia.

Methods

A survey of patients with diabetes, who had visited seven tertiary referral centers in Daegu or Gyeongsangbuk-do, Korea, between June 2014 and June 2015, was conducted. The survey contained questions about personal history, symptoms, educational experience, self-management, and attitudes about hypoglycemia.

Results

Of 758 participants, 471 (62.1%) had experienced hypoglycemia, and 250 (32.9%) had experienced hypoglycemia at least once in the month immediately preceding the study. Two hundred and forty-two (31.8%) of the participants had received hypoglycemia education at least once, but only 148 (19.4%) knew the exact definition of hypoglycemia. Hypoglycemic symptoms identified by the participants were dizziness (55.0%), sweating (53.8%), and tremor (40.8%). They mostly chose candy (62.1%), chocolate (37.7%), or juice (36.8%) as food for recovering hypoglycemia. Participants who had experienced hypoglycemia had longer duration of diabetes and a higher proportion of insulin usage. The mean scores for hypoglycemia avoidance behavior and worry about hypoglycemia were 21.2±10.71 and 23.38±13.19, respectively. These scores tended to be higher for participants with higher than 8% of glycosylated hemoglobin, insulin use, and experience of emergency room visits.

Conclusion

Many patients had experienced hypoglycemia and worried about it. We recommend identifying patients that are anxious about hypoglycemia and educating them about what to do when they develop hypoglycemic symptoms, especially those who have a high risk of hypoglycemia.

Citations

Citations to this article as recorded by

Severe Hypoglycemia Increases Dementia Risk and Related Mortality: A Nationwide, Population-based Cohort Study
Eugene Han, Kyung-do Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Seung-Hyun Ko, Yong-ho Lee
The Journal of Clinical Endocrinology & Metabolism.2022; 107(5): e1976. CrossRef
Severe hypoglycemia as a preventable risk factor for cardiovascular disease in patients with type 2 diabetes mellitus
Soo-Yeon Choi, Seung-Hyun Ko
The Korean Journal of Internal Medicine.2021; 36(2): 263. CrossRef
Severe hypoglycemia and the risk of end stage renal disease in type 2 diabetes
Jae-Seung Yun, Yong-Moon Park, Kyungdo Han, Hyung-Wook Kim, Seon-Ah Cha, Yu-Bae Ahn, Seung-Hyun Ko
Scientific Reports.2021;[Epub] CrossRef
Response: Patient Understanding of Hypoglycemia in Tertiary Referral Centers (Diabetes Metab J 2018;42:43-52)
Nan Hee Cho, Hye Soon Kim
Diabetes & Metabolism Journal.2018; 42(2): 175. CrossRef
Letter: Patient Understanding of Hypoglycemia in Tertiary Referral Centers (Diabetes Metab J 2018;42:43-52)
Jae-Han Jeon
Diabetes & Metabolism Journal.2018; 42(2): 173. CrossRef

Reviews

Clinical Diabetes & Therapeutics
Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians: Ahmed Iqbal, Peter Novodvorsky, Simon R. Heller; Diabetes Metab J. 2018;42(1):3-18. Published online February 23, 2018; DOI: https://doi.org/10.4093/dmj.2018.42.1.3

6,037 View
81 Download
17 Citations

Abstract PDF PubReader

Type 1 diabetes mellitus (T1DM) is a chronic autoimmune condition that requires life-long administration of insulin. Optimal management of T1DM entails a good knowledge and understanding of this condition both by the physician and the patient. Recent introduction of novel insulin preparations, technological advances in insulin delivery and glucose monitoring, such as continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring and improved understanding of the detrimental effects of hypoglycaemia and hyperglycaemia offer new opportunities and perspectives in T1DM management. Evidence from clinical trials suggests an important role of structured patient education. Our efforts should be aimed at improved metabolic control with concomitant reduction of hypoglycaemia. Despite recent advances, these goals are not easy to achieve and can put significant pressure on people with T1DM. The approach of physicians should therefore be maximally supportive. In this review, we provide an overview of the recent advances in T1DM management focusing on novel insulin preparations, ways of insulin administration and glucose monitoring and the role of metformin or sodium-glucose co-transporter 2 inhibitors in T1DM management. We then discuss our current understanding of the effects of hypoglycaemia on human body and strategies aimed at mitigating the risks associated with hypoglycaemia.

Citations

Citations to this article as recorded by

Nose-to-brain delivery of insulin nanoparticles for diabetes management: A review
Manoj Kumbhare, Ajaykumar Surana, Pravin Morankar
Baghdad Journal of Biochemistry and Applied Biological Sciences.2023;[Epub] CrossRef
Clinical Effects of a Home Care Pilot Program for Patients with Type 1 Diabetes Mellitus: A Retrospective Cohort Study
Sejeong Lee, KyungYi Kim, Ji Eun Kim, Yura Hyun, Minyoung Lee, Myung-Il Hahm, Sang Gyu Lee, Eun Seok Kang
Diabetes & Metabolism Journal.2023; 47(5): 693. CrossRef
Role of sirtuin-1 (SIRT1) in hypoxic injury in pancreatic β-cells
Ye-Jee Lee, Esder Lee, Young-Hye You, Yu-Bae Ahn, Ki-Ho Song, Ji-Won Kim, Seung-Hyun Ko
Journal of Drug Targeting.2021; 29(1): 88. CrossRef
Age at Diagnosis and the Risk of Diabetic Nephropathy in Young Patients with Type 1 Diabetes Mellitus
Jong Ha Baek, Woo Je Lee, Byung-Wan Lee, Soo Kyoung Kim, Gyuri Kim, Sang-Man Jin, Jae Hyeon Kim
Diabetes & Metabolism Journal.2021; 45(1): 46. CrossRef
The impact of chemical engineering and technological advances on managing diabetes: present and future concepts
Sabine Szunerits, Sorin Melinte, Alexandre Barras, Quentin Pagneux, Anna Voronova, Amar Abderrahmani, Rabah Boukherroub
Chemical Society Reviews.2021; 50(3): 2102. CrossRef
Surrogate markers and predictors of endogenous insulin secretion in children and adolescents with type 1 diabetes
Jin-Na Yuan, Jian-Wei Zhang, Wayne S. Cutfield, Guan-Ping Dong, You-Jun Jiang, Wei Wu, Ke Huang, Xiao-Chun Chen, Yan Zheng, Bi-Hong Liu, José G. B. Derraik, Jun-Fen Fu
World Journal of Pediatrics.2021; 17(1): 99. CrossRef
Nano-based drug delivery systems used as vehicles to enhance polyphenols therapeutic effect for diabetes mellitus treatment
Sónia Rocha, Mariana Lucas, Daniela Ribeiro, M. Luísa Corvo, Eduarda Fernandes, Marisa Freitas
Pharmacological Research.2021; 169: 105604. CrossRef
Dapagliflozin: an effective adjunctive treatment in type 1 diabetes
Ghasem Yadegarfar, Mark Livingston, Gabriela Cortes, Ramadan Alshames, Kate Leivesley, Ann Metters, Linda Horne, Tom Steele, Adrian H. Heald
Cardiovascular Endocrinology & Metabolism.2021; 10(2): 132. CrossRef
Association between reduced serum levels of magnesium and the presence of poor glycemic control and complications in type 1 diabetes mellitus: A systematic review and meta-analysis
Ana Kelen Rodrigues, Ana Elisa Melo, Caroline Pereira Domingueti
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(2): 127. CrossRef
Insulin-Producing Cell Transplantation Platform for Veterinary Practice
Suryo Kuncorojakti, Sayamon Srisuwatanasagul, Krishaporn Kradangnga, Chenphop Sawangmake
Frontiers in Veterinary Science.2020;[Epub] CrossRef
Type 1 Diabetes Home Care Project and Educational Consultation
Eun Chong Shin
The Journal of Korean Diabetes.2020; 21(2): 88. CrossRef
Decision-Making in Artificial Intelligence: Is It Always Correct?
Hun-Sung Kim
Journal of Korean Medical Science.2020;[Epub] CrossRef
The FreeStyle Libre flash glucose monitoring system: how it has improved glycaemic control for people with type 1 diabetes in Eastern Cheshire, UK
Ghasem Yadegarfar, Simon G. Anderson, Zohaib Khawaja, Gabriela Cortes, Kathryn Leivesley, Ann Metters, Linda Horne, Tom Steele, Adrian H. Heald
Cardiovascular Endocrinology & Metabolism.2020; 9(4): 171. CrossRef
Dose-dependent effects of necrostatin-1 supplementation to tissue culture media of young porcine islets
Hien Lau, Nicole Corrales, Samuel Rodriguez, Colleen Luong, Mohammadreza Mohammadi, Veria Khosrawipour, Shiri Li, Michael Alexander, Paul de Vos, Jonathan R. T. Lakey, Zoltán Rakonczay
PLOS ONE.2020; 15(12): e0243506. CrossRef
New Insulin Pumps and Open Source Artificial Pancreas System in Korea
Jae Hyeon Kim
The Journal of Korean Diabetes.2020; 21(4): 197. CrossRef
Perspective and general approach of diabetes in palliative care
Díaz Rodríguez Juan Javier
Hospice and Palliative Medicine International Journal.2018;[Epub] CrossRef
The effects of safranal, a constitute of saffron, and metformin on spatial learning and memory impairments in type-1 diabetic rats: behavioral and hippocampal histopathological and biochemical evaluations
Fatemeh Delkhosh-Kasmaie, Amir Abbas Farshid, Esmaeal Tamaddonfard, Mehdi Imani
Biomedicine & Pharmacotherapy.2018; 107: 203. CrossRef

Clinical Diabetes & Therapeutics
Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association: Hyun Jin Kim, Seok O Park, Seung-Hyun Ko, Sang Youl Rhee, Kyu-Yeon Hur, Nan-Hee Kim, Min Kyong Moon, Byung-Wan Lee, Jin Hwa Kim, Kyung Mook Choi; Diabetes Metab J. 2017;41(6):423-429. Published online December 19, 2017; DOI: https://doi.org/10.4093/dmj.2017.41.6.423

5,112 View
65 Download
6 Citations

Abstract PDF PubReader

The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The cardiovascular safety of GLP-1RAs has been assessed in several randomized clinical trials and systematic reviews. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.

Citations

Citations to this article as recorded by

Anti-inflammatory effect of glucagon-like Peptide-1 receptor agonist on the neurosensory retina in an acute optic nerve injury rat model
Yeon Woong Chung, Ji Young Lee, Hyun Hee Ju, Jin A. Choi
European Journal of Pharmacology.2022; 933: 175269. CrossRef
Diabetes Risk Data Mining Method Based on Electronic Medical Record Analysis
Yang Liu, Zhaoxiang Yu, Yunlong Yang, Zhihan Lv
Journal of Healthcare Engineering.2021; 2021: 1. CrossRef
Paradigm Shift for the Treatment of Type 2 Diabetes Mellitus in Patients with Cardiovascular Disease: Cardiologist's Perspective
Doo Soo Jeon
Cardiovascular Prevention and Pharmacotherapy.2020; 2(1): 11. CrossRef
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia
Ju-Ming Lu
Advances in Therapy.2019; 36(4): 798. CrossRef
A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes
Irene Romera, Ana Cebrián-Cuenca, Fernando Álvarez-Guisasola, Fernando Gomez-Peralta, Jesús Reviriego
Diabetes Therapy.2019; 10(1): 5. CrossRef
Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
Hyun Jin Kim
The Journal of Korean Diabetes.2018; 19(1): 35. CrossRef

Original Article

Complications
Baseline-Corrected QT (QTc) Interval Is Associated with Prolongation of QTc during Severe Hypoglycemia in Patients with Type 2 Diabetes Mellitus: Seon-Ah Cha, Jae-Seung Yun, Tae-Seok Lim, Yoon-Goo Kang, Kang-Min Lee, Ki-Ho Song, Ki-Dong Yoo, Yong-Moon Park, Seung-Hyun Ko, Yu-Bae Ahn; Diabetes Metab J. 2016;40(6):463-472. Published online October 5, 2016; DOI: https://doi.org/10.4093/dmj.2016.40.6.463

3,253 View
46 Download
10 Citations

Abstract PDF PubReader

Background

We investigated an association between baseline heart rate-corrected QT (QTc) interval before severe hypoglycemia (SH) and prolongation of QTc interval during SH in patients with type 2 diabetes mellitus (T2DM).

Methods

Between January 2004 and June 2014, 208 patients with T2DM, who visited the emergency department because of SH and underwent standard 12-lead electrocardiography within the 6-month period before SH were consecutively enrolled. The QTc interval was analyzed during the incidence of SH, and 6 months before and after SH. QTc intervals of 450 ms or longer in men and 460 ms or longer in women were considered abnormally prolonged.

Results

The mean age and diabetes duration were 68.1±12.1 and 14.1±10.1 years, respectively. The mean QTc intervals at baseline and SH episodes were 433±33 and 460±33 ms, respectively (P<0.001). One hundred and fourteen patients (54.8%) had a prolonged QTc interval during SH. There was a significant decrease in the prolonged QTc interval within 6 months after SH (QTc interval prolongation during SH vs. after recovery, 54.8% vs. 33.8%, P<0.001). The prolonged QTc interval was significantly associated with baseline QTc interval prolongation (odds ratio, 2.92; 95% confidence interval, 1.22 to 6.96; P=0.016) after adjusting for multiple confounders.

Conclusion

A prolonged QTc interval at baseline was significantly associated with prolongation of the QTc interval during SH in patients with T2DM, suggesting the necessity of QTc interval monitoring and attention to those with a prolonged QTc interval to prevent SH.

Citations

Citations to this article as recorded by

Prevalence of QT prolongation and its risk factors in patients with type 2 diabetes
Khaled Aburisheh, Mohammad F. AlKheraiji, Saleh I. Alwalan, Arthur C. Isnani, Mohamed Rafiullah, Muhammad Mujammami, Assim A. Alfadda
BMC Endocrine Disorders.2023;[Epub] CrossRef
U-shaped association between the triglyceride–glucose index and atrial fibrillation incidence in a general population without known cardiovascular disease
Xiao Liu, Ayiguli Abudukeremu, Yuan Jiang, Zhengyu Cao, Maoxiong Wu, Jianyong Ma, Runlu Sun, Wanbing He, Zhiteng Chen, Yangxin Chen, Peng Yu, Wengen Zhu, Yuling Zhang, Jingfeng Wang
Cardiovascular Diabetology.2023;[Epub] CrossRef
Celebrities in the heart, strangers in the pancreatic beta cell: Voltage‐gated potassium channels Kv7.1 and Kv11.1 bridge long QT syndrome with hyperinsulinaemia as well as type 2 diabetes
Anniek F. Lubberding, Christian R. Juhl, Emil Z. Skovhøj, Jørgen K. Kanters, Thomas Mandrup‐Poulsen, Signe S. Torekov
Acta Physiologica.2022;[Epub] CrossRef
Severe hypoglycemia as a risk factor for cardiovascular outcomes in patients with type 2 diabetes: is it preventable?
Seung-Hyun Ko
Cardiovascular Prevention and Pharmacotherapy.2022; 4(3): 106. CrossRef
Heart rate-corrected QT interval prolongation is associated with decreased heart rate variability in patients with type 2 diabetes
Seon-Ah Cha
Medicine.2022; 101(45): e31511. CrossRef
Severe hypoglycemia as a preventable risk factor for cardiovascular disease in patients with type 2 diabetes mellitus
Soo-Yeon Choi, Seung-Hyun Ko
The Korean Journal of Internal Medicine.2021; 36(2): 263. CrossRef
Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial
Marile Santamarina, Curt J. Carlson
BMC Cardiovascular Disorders.2019;[Epub] CrossRef
Antioxidant effects of epigallocatechin-3-gallate on the aTC1-6 pancreatic alpha cell line
Ting Cao, Xiong Zhang, Dan Yang, Yue-Qian Wang, Zheng-Dong Qiao, Jian-Ming Huang, Peng Zhang
Biochemical and Biophysical Research Communications.2018; 495(1): 693. CrossRef
Severe hypoglycemia is a risk factor for atrial fibrillation in type 2 diabetes mellitus: Nationwide population-based cohort study
Seung-Hyun Ko, Yong-Moon Park, Jae-Seung Yun, Seon-Ah Cha, Eue-Keun Choi, Kyungdo Han, Eugene Han, Yong-ho Lee, Yu-Bae Ahn
Journal of Diabetes and its Complications.2018; 32(2): 157. CrossRef
Incidence of prolonged QTc and severe hypoglycemia in type 1 diabetes: the EURODIAB Prospective Complications Study
Cristina Amione, Sara Giunti, Paolo Fornengo, Sabita S. Soedamah-Muthu, Nish Chaturvedi, J. H. Fuller, Federica Barutta, Gabriella Gruden, Graziella Bruno
Acta Diabetologica.2017; 54(9): 871. CrossRef

First
Prev
Page of 2
Next
Last

Search